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ORIGINAL PUBLICATIONS
This dissertation is based on the following publications on metastatic uveal melanoma. The
original publications in the text will be referred to by their Roman numerals I-IV:
I Eskelin S, Pyrhönen S, Summanen P, Prause JU, Kivelä T. Screening for
metastatic malignant melanoma of the uvea revisited. Cancer 1999: 85; 1151-9.
II Eskelin S, Pyrhönen S, Summanen P, Hahka-Kemppinen M, Kivelä T. Tumor
doubling times in metastatic malignant melanoma of the uvea: Tumor
progression before and after treatment. Ophthalmology 2000: 107; 1443-1449.
III Eskelin S, Pyrhönen S, Hahka-Kemppinen M, Tuomaala S, Kivelä T. A
prognostic model and staging for metastatic uveal melanoma. Cancer 2003:
97(2); 465-475.
IV Eskelin S, Kivelä T. Efficacy of referral to treatment of primary malignant
melanoma of the uvea in Finland. Br J Ophthalmol 2002: 86; 333-338.
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ABBREVIATIONS
ALT Alanine Aminotransferase (enzyme)
AP Alkaline Phosphatase (enzyme)
AST Aspartate Aminotransferase (enzyme)
CI Confidence interval
COMS The Collaborative Ocular Melanoma Study
CT Computed tomography
DT Doubling time
DTIC Dacarbazine (chemotherapeutic)
ECOG Eastern Cooperative Oncology Group
EORTC European Organization for Research and Treatment of Cancer
FAG Fluorescein angiography
FNAB Fine needle aspiration biopsy
GGT Gamma Glutamyl Transferase (enzyme)
HLA Human leukocyte Antigen
HR Hazard ratio
HUCH Helsinki University Central Hospital
IOP Intraocular pressure
LBD Largest basal diameter
LD Lactate Dehydrogenase (enzyme)
LFT Liver function test
MRI Magnetic resonance imaging
MVD Microvascular density
N/A Not applicable
PAD Pathologic-anatomical diagnosis
ROC Receiver Operating Characteristics (curve)
TNM Tumor-node-metastasis
TTT Transpupillary thermotherapy
UNL Upper normal limit of a serum enzyme level
US Ultrasonography
UV Ultraviolet
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1. ABSTRACT
This study was undertaken to advance the understanding of development of metastatic uveal
melanoma and to improve treatment and prognosis of patients. Two of the studies (I, IV)
concentrated on minimizing delays in diagnosis of primary uveal melanoma and metastases.
The second study (II) was carried out to understand and estimate the growth kinetics of
tumors and timing of the crucial processes. Study (III) tried to address the problematic lead
time bias and to identify independent prognostic factors in modeling survival after
disseminated disease so that the results of treatment trials could be more efficiently reported
and evaluated.
I. Annual screening programs for metastatic uveal melanoma are carried out to detect
metastases early, when they are small and potentially easier to treat. It was shown that two
thirds of the patients were diagnosed as asymptomatic when screening is annual, and that
semiannual screening would detect up to 98% patients as asymptomatic. Abdominal US
revealed definite metastases or led to a diagnostic CT scan, fine needle aspiration biopsy, or
both in 89% of patients. The LFTs supported the findings of abdominal US which was
superior to chest radiograms. As a result chest x-rays were dropped from the program.
II. The calculated doubling times were used to roughly predict the behavior of the metastases
in the period prior to diagnosis. The calculated time of micrometastasis relative to the time of
treatment of the primary tumor showed that the majority of primary tumors, assuming a
constant growth rate, would have metastasized within 1 to 3 years before diagnosis and
treatment.
III. The analysis showed that patients who participated in the annual screening to detect
disseminated disease tended to survive longer after diagnosis of metastases. This difference
could be due to lead-time bias. Until now, estimating the effect of lead-time bias and
stratification of patients by their estimated prognosis in treatment trials has not been possible.
A multivariate model was built and a table of predicted median survival time after diagnosis
of metastases was compiled for clinically relevant combinations of Karnofsky index, serum
AP level and the largest dimension of the largest metastasis which all were found to have
independent predictive value.
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IV. Is it possible to make the diagnosis of uveal melanoma earlier so as to decrease odds of
metastasis? One eighth of our patients were asymptomatic and the primary tumor was
diagnosed during a routine visit. In Finland, two thirds of patients with uveal melanoma
sought help directly from an ophthalmologist whether they had symptoms or not. Their
chance of being immediately referred and correctly diagnosed at first visit was 88% and 71%,
respectively. The observed median delay of less than 4 months from the onset of symptoms of
primary tumor to treatment may not represent a serious hazard to life, but a shorter delay
could potentially salvage more useful vision and perhaps prevent some metastases from
developing.
At the time of micrometastasis, the primary tumor was estimated to be small, but one that
should easily be detected by ophthalmoscopy. Small tumors are more likely to escape
detection as even large tumors are missed by ophthalmologists, or to be interpreted as nevi.
Uveal nevi may turn malignant. Follow-up of presumed nevi is ideally based on fundus
photographs and, when the nevus is elevated, on ultrasonographic measurements. The tumors
in our study were on average almost twice as large by LBD at diagnosis of uveal melanoma
than initially, but their median volume was seven times bigger. Earlier growth was thus likely
missed or disregarded which emphasizes the importance of referring small suspicious tumors
for second opinion at an early stage. The estimates of early metastatic potential might perhaps
also be viewed as an indication to reconsider the policy of following small suspicious
pigmented tumors without treatment.
The inability of modern treatments of primary uveal melanoma and of current chemotherapy
regimens for disseminated disease to notably improve prognosis calls for efforts to help the
immune system to fight micrometastasis at an early stage and to develop other adjuvant
therapies to be used at the time of the treatment of the primary tumor.
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2. INTRODUCTION
Uveal melanoma – a threat to both vision and life – is a relatively rare cancer but the
second most common type of primary malignant melanoma in humans and the most common
primary intraocular malignancy.
Uveal melanoma develops from melanocytes situated in the most vascular part of the eye,
i.e. the uvea. The uvea consists of the flat choroid which covers ¾ of the posterior segment of
the eye between the white hard sclera and the seeing retina, the ciliary body which supports
the lens and secretes aqueous humor in the anterior segment of the eye, and the iris.
Uveal melanoma is remarkable for its purely hematogenous dissemination and a tendency
to metastasize to the liver.49;89;157 Half of the patients die of metastasis within 15 years. Iris
melanomas differ greatly from other uveal melanomas by better prognosis. Until the late
1970’s, an eye with a uveal melanoma was enucleated and since then various radiation and
other surgical therapies have been available. These new treatments have not improved
prognosis.
 The prognosis of metastatic uveal melanoma has been poor with a median overall survival
from 2 to 9 months.16;58;70;110 Although median survival of up to 24 months is now reported,
the factors contributing to improved prognosis have not been critically analyzed.43;75;113
Because many enrolled patients participated in regular screening and were asymptomatic,
lead-time bias must be taken into account. So far, patients enrolled in treatment trials for
metastatic disease have not been categorized and no tools have been available to adjust for
differences in case mix between trials. This is extremely important when evaluating treatment
effect in this typically rapidly progressing phase of the disease. For this reason, working
formulation for staging of patients was developed.
A logical way to improve the survival of cancer patients is to diagnose their tumors earlier
when they are small, to decrease the risk of metastasis. The delays in the diagnosis and
treatment of primary uveal melanoma have been studied so far only in U.K. We do not know
how much earlier diagnosis would be clinically effective.
The purpose of this study was to enlighten the prognostic significance of factors related to
the screening program of patients with uveal melanoma and to present an estimation of the
possible lead time bias in survival in treatment trials. In addition, critical evaluation of
efficacy of both the current health care system to detect and treat primary tumors and the
current screening program to detect metastases was called for in order to minimize treatment
delays.
Review of Literature
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3. REVIEW OF LITERATURE
3.1. Epidemiology of uveal melanoma
Uveal melanoma affects from 6 to 12 patients per 1 million inhabitants per year in
Caucasian populations.18 Raivio et al. estimated in 1977 that during the years 1953-1973 the
annual incidence in Finland was 5 per 1 million corresponding to a total of 25 patients per
year.109 According to more recent data the annual incidence in males and females varied from
7.5 to 11.0 and from 6.9 to 8.8 per million, respectively, during 1955-1994.140 This apparent
change may be due to the incompleteness of the Finnish Cancer registry in its early years in
the 1950’s. In Denmark, an annual incidence of 7.1 and in Sweden an incidence of 7.2 and,
recently, up to 12 per million have been reported.2;18;69 In large, age-adjusted series uveal
melanoma is reported to be more common in males.18;18;42 The higher rates in men may
suggest an independent effect of gender or some unknown exposure that is more common
among males.42 In Finland, the difference between genders is inverse which may be due to the
fact that females tend to survive longer and hence can develop more malignant tumors during
their lifetime.
Melanomas of the skin and conjunctiva150 have been increasing in frequency over the last
several decades, while such a trend has not been proved as regards uveal melanoma.
Uveal melanoma is rarely bilateral. Singh and associates found eight patients with bilateral
uveal melanoma in a clinical series of 4,500 cases.133 No specific predisposing syndrome was
identified other than ocular melanocytosis in two of the eight patients. The COMS group
identified 10 bilateral uveal melanomas in a large clinical series of 8712 patients.35 This
results in an estimated incidence of 1 per 734 uveal melanoma patients.
Clinical metastases are evident in 0.2 – 2.5% of patients at the diagnosis of primary uveal
melanoma.35;99;153
3.2. Predisposing Factors
3.2.1. Age
The mean age at diagnosis is 50-60 years.42 The risk of uveal melanoma increases with
age, but seems to level off after the age of 70, more so with females.109 This is different from
other adult cancers in which the risk increases with age.42
Review of Literature
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3.2.2. Race
Light complexion and blue eyes are also predisposing factors for increased risk for uveal
melanoma.42 Caucasians have more than 8 times greater risk of developing the disease
compared with Africans.42 The risk of uveal melanoma is also low in races of intermediate
pigmentation like Orientals and native Americans.25;42;132;154
3.2.3. Nevi
A high number of nevi, especially dysplastic nevi, on the skin have been shown to increase
the risk of cutaneous melanoma.28 Uveal nevi seem to have low risk of progressing to uveal
melanoma. The estimated incidence of choroidal nevi ranges from 3 to 20%.158 Only rough
estimates of the incidence of choroidal nevi transforming into uveal melanoma have been
presented (1 in 15000).158
In case of small choroidal tumors, including nevi, the following high risk characteristics
have been identified: presence of symptoms and subretinal fluid, tumor thickness greater than
2 mm, orange lipofuscin pigment over the tumor, and tumor margin touching the optic
disc.123;127 The COMS group has identified as additional risk factors larger basal diameter,
and absence of drusen and retinal pigment epithelial changes adjacent to tumor.144 Any one of
these factors raises the risk for growth, which often is a sign of malignancy, the more so when
occurring together. Shields et al. calculated the relative risk for growth to be 1.9 for one
factor, 3.8 for 2 factors, 7.4 for 3 factors, 14.1 for 4 factors, and 27.1 for all 5 of their risk
factors combined.123
3.2.4. Ocular and oculodermal melanocytosis
Ocular and oculodermal melanocytosis (nevus of Ota) are congenital pigmentary
anomalies that typically involve at least episclera and uveal tract.57 Gonder et al suggested
that the ocular and oculodermal melanocytosis increase the relative risk for uveal melanoma
by a maximum of 35 times.57
3.2.5. Sunlight exposure
Development of cutaneous melanoma has been linked to UV-light exposure. Because uveal
melanomas develop from melanocytes, sunlight has been proposed as a risk factor.
Contradicting evidence has been presented in favor and against the causative role of sunlight
exposure in uveal melanoma, but the body of evidence favors little or no effect. If sunlight
would increase the risk for uveal tumors, a general rise in incidence might be expected.42 No
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clear evidence has been presented that geographical latitude would have a consistent effect on
incidence.42;119 The incidence of uveal melanoma is not increased in xeroderma pigmentosum
patients who are extremely sensitive to short ultraviolet wavelengths and develop cutaneous
melanoma frequently.102 The adult cornea and lens are effective UV-A and UV-B filters
which allow virtually no transmission.156 The juvenile lens, however, may transmit some UV
radiation to the posterior segment of the eye.
Sunlight may also weaken systemic immune defense. In this case, increase in tumors
would be expected, but this has not been evident.42
Three studies have compared sunlight exposure histories of uveal melanoma patients with
those of controls. One identified sunlight as a risk factor, but of various exposure habits
assessed only gardening and not protecting eyes while outside were significantly more
common among patients.149 The other did not found any association between sunlight
exposure and uveal melanoma.53 The third study identified intense exposure with increased
risk but also contradictory association of birthplace below latitude 40 degrees N and outdoor
work with a lower risk119
3.2.6. Tobacco
Smoking is suspected of altering immune defense mechanisms and may therefore enhance
the growth of metastases among cancer patients. Smoking did not have any effect on the
development of uveal melanoma metastases during the first years after the diagnosis of
primary tumor.40 As uveal melanoma is a slowly progressing disease, longer follow-up, up to
15 to 20 years, is needed to verify this.
3.2.7. Endocrinology
It has been suggested that pregnancy may enhance growth and metastases in melanoma.41
However, large series of uveal melanoma patients fail to support this assertion.125 A search for
estrogen and progesterone receptors in choroidal melanoma showed no evidence for such
receptors.61;82;120
3.3. Diagnosis
Uveal melanomas are solid intraocular tumors. Choroidal tumors are located between
retinal pigment epithelium and sclera. Tumors can also arise from other parts of the uvea –
from ciliary body and iris. The surface of some uveal melanomas particularly in the posterior
pole shows a patchy orange pigmentation, which is lipofuscin in macrophages and retinal
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pigment epithelium. A secondary exudative retinal detachment adjacent to the choroidal
tumor occurs frequently and this can be responsible partly for visual loss.72 Usual symptoms
are blurred vision and loss of visual field.67 In addition, there can be retinal degeneration with
pigmentary changes overlying the apex of the tumor. Frequently, a choroidal melanoma
breaks through Bruch’s membrane, extending into the subretinal space. The tumor can also
grow through the retina and lead to intravitreous hemorrhages. While a circumscribed tumor
is the most frequent configuration, uveal melanomas can take on a diffuse pattern in which
large areas of the uveal tract are thickened. Melanomas can diffusely involve the ciliary body
in a pattern called “ring melanoma”. Such tumors can be difficult to diagnose because there is
relatively little visible mass effect and ciliary body is a diagnostically difficult area of the
eye.23;34 In addition, patients with retinoinvasive diffuse melanoma have been reported.73 It is
a rarely diagnosed but distinct entity, different from circumscribed and most diffuse
melanomas that may erode the overlying retina and infiltrate the optic nerve, but which do not
invade non-adjacent retina.
The Collaborative Ocular Melanoma Study Group reports that clinical diagnosis by
ophthalmic oncologist is accurate in over 98% of instances when tumor size is medium or
large.142 The smaller the tumor is, that the harder it is to diagnose it correctly when first seen.
Many small tumors require follow-up to verify growth. Comprehensive indirect
ophthalmoscopy or slit-lamp biomicroscopy are the main diagnostic methods supported by A-
and B-scan ultrasonography, fluorescein angiography, indocyanine green angiography, and
orbital CT-scan and MRI.
Ultrasound is particularly useful in the diagnosis of melanoma in eyes in which the
posterior pole cannot be visualized directly. It is an inexpensive method which can give
accurate measures and help in localization of the tumor. Uveal melanoma has also distinct
echogram in which the reflectivity decreases linearly within the tumor in contrast to other
uveal tumors. It is also an excellent follow-up method to document growth of small tumors
and regression or relapse of treated tumors. High-frequency ultrasonography (ultrasound
biomicroscopy) can be used in diagnosis of anterior tumors.88
FAG lends support to diagnosis but is not always required. Approximately two thirds of
cases in one series showed a "double circulation" pattern, which is characteristic for uveal
melanoma.9 Indocyanine green angiography shows details of choroidal circulation more
effectively. Combined with scanning laser confocal microscopy to study the tumor
vasculature it may help in estimating the prognosis in the future.95
Patients are also examined thoroughly to verify the absence of other cancer.
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Histologic or cytologic specimens are rarely obtained for diagnosis of uveal melanoma, in
contrast to most other cancers.130 This procedure may increase the risk of local spread and
vision loss, and the sampled area may not be representative of the entire tumor.51
A biopsy is required if the diagnosis of uveal melanoma is in doubt and alternative
diagnosis would lead to different treatment. The indications for biopsy should be carefully
evaluated because of complications. A needle biopsy can be taken guiding the needle through
sclera or cornea directly into the tumor.15 This method may increase the risk of extraocular
growth through the canal. Others take the biopsy through the vitreous cavity under visual
control.15 This method needs also intraocular infusion to control for possible hemorrhage.
With this method, intraocular dissemination within the vitreous is possible.
Differential diagnoses that have to be considered are for instance metastasis to the eye
(especially breast and lung cancer), choroidal nevus, melanocytoma, hemangioma, osteoma,
uveitis, and retinal detachment. The confirmation of diagnosis of uveal melanoma is based on
typical clinical or intraocular US findings and on the fact that no additional tumors are found
elsewhere by imaging.
3.4. Screening and follow-up
The potential effect of early diagnosis and treatment of ocular melanoma should not be
disregarded, especially as they might also allow better preservation of vision in eyes that are
treated with conservative methods.3;30;31 Because the incidence of uveal melanoma is low, it is
not feasible to mass screen even the age groups which would be at highest risk of developing
it.42 Moreover, a comprehensive ophthalmologic examination would be needed instead of a
simple screening test. Consequently, mainly patients with suspicious choroidal nevi and
congenital melanocytosis are presently reviewed by many ophthalmologists and most ocular
oncologists with varying intervals.20;57
The question of whether to follow up choroidal nevi to detect uveal melanoma earlier, to
treat suspicious nevi immediately or to refrain from follow-up has been under
debate.20;123;127;144 The time schedule of the follow-up program is currently individualized.
How patients are diagnosed to have primary uveal melanoma and how they are referred to
treatment is known in detail only for the United Kingdom. 3;30;31;67 Out of 50 patients, 72%
had symptoms at diagnosis, the rest were diagnosed during the course of a routine eye test.
42% of patients were considered to have experienced delays in diagnosis and treatment and
they were more likely to have been treated by enucleation than eye-conserving method.3;67
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Table 1. The number of practicing dispensing opticians, optometrists, general practitioners,
and ophthalmologists per 100 000 inhabitants in Finland and U.K.
Profession Finland U.K.
Dispensing optician*,† 25.7   6.7
Optometrists† N/A‡ 14.5
General practitioner¶,§ 69.5 57.3
Ophthalmologist¶,**   8.8   1.4
*The Association of Finnish Opticians
† The College of Optometrists (www.college-optometrists.org)
‡ Ophthalmic opticians and optometrists not currently licensed, not applicable
§ StatBase (www.statistics.gov.uk)
¶ Finnish Medical Association
**Dernouchamps J-P. UEMS Compendium of Medical Specialists 2000, Kensington Publications Ltd
United Kingdom has a special type of health care system based on many ophthalmic
opticians and general practitioners and relatively few ophthalmologists (Table 1).3;67
In Finland, ophthalmic opticians and optometrists are not licensed, and patients contact an
ophthalmologist, a family physician, or a dispensing optician instead (Table 1). The
dispensing opticians, who do not do dilated fundus examinations, are obliged to refer their
customer to a physician if they suspect disease. When the diagnosis of an intraocular tumor is
made or suspected, staging examinations are carried out usually at regional hospitals and the
patient is thereafter referred as a rule to a single ocular oncology service in Helsinki.
3.5. Treatment – Primary Tumor
Irradiation with plaque brachytherapy is the main treatment method of uveal melanoma in
Finland.139 The plaque is shielded to radiate only towards eye. It is surgically placed on the
sclera, over the uveal tumor, and is removed later after the calculated total radiation dose has
been delivered. Several different isotopes have been used including cobalt 60, ruthenium 106,
iodine 125, and palladium 103.48
Typically ruthenium plaques are used for melanomas less than 6 mm in height, and those
that are over 6 mm in height are usually treated with iodine plaques. Enucleation is done
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routinely when conservative therapy is not technically feasible. Transpupillary thermotherapy
(TTT) with infrared diode laser is mainly used as adjuvant therapy and may be useful in
selected cases.122 Compared with enucleation the patient will often have useful vision
remaining and will not often suffer from cosmetic disturbances. Patients may also benefit
psychologically from the salvation of the globe but some may be more comfortable when “the
evil” is taken away by enucleation. The treatment should be based on knowledge and
understanding between the patient and ocular oncologist.29
The management of uveal melanoma is similar in the other Nordic countries, especially in
Sweden and Denmark.121 In other European countries enucleation, proton beam radiotherapy,
gamma-knife surgery, and transscleral local resection are also used.32;87 In U.S. most patients
are treated with brachytherapy, proton beam radiotherapy, and enucleation.130
In Finland the management of the primary uveal melanoma is centralized into the
Oncology Service of the Department of Ophthalmology, Helsinki University Central Hospital.
Few patients, about 5% with advanced tumors, are still treated by enucleation in regional
hospitals. In these cases the removed eye is often sent to the Ocular Pathology Laboratory,
HUCH, which co-operates closely with the Oncology Service.
3.6. Prognosis
Single dose ruthenium and iodine brachytherapies have a 63-80% and 93% 5-year
probability for local tumor control, respectively.77;96;100 In few cases supplementary laser
photocoagulation is performed.65 Proton beam irradiation has a 97% 5-year probability for
local tumor control.59 Compared with proton beam irradiation, brachytherapy has less adverse
effects outside globe. Because the radiation dose is delivered externally, anterior structures
receive more radiation with proton beams than they would with a plaque.48
Local recurrence is reported to be a risk for systemic metastasis.24;59;65 Even though
regrowth is not clinically evident, viable cells are reported to be present after radiation with
unknown potential for dissemination.103;115 The possibility of cells losing their viability and
still remaining positive for cell proliferation markers was addressed in Schilling’s study.115
Secondary enucleation is done to the few patients with uveal melanoma who experience
pain, phtisis, uncontrollable IOP or their tumor is resistant to the irradiation.126
The visual acuity and field of vision are in danger despite the shrinkage of the tumor.
Radiation retinopathy is an unavoidable complication and it develops a median of 2 to 3 years
after treatment.100 The prognosis of the vision is dependent on the size and location of the
tumor relative to optic disc, macula and lens, the radiation dose, and the dose rate.48;124
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Regional disease is relatively rare nowadays as primary tumors are diagnosed early enough
not to have extraocular extensions. If extraocular extensions are present in advanced uveal
melanomas orbital exenteration may be justified but likely does not prevent metastasis.129
Malignant melanoma of the uvea is a cancer that disseminates in one half of cases within
ten years.16;21;37;69;78 Modern diagnostic and therapeutic methods have not been able to reduce
the frequency of dissemination as compared with enucleation.12;36
3.7. Prognostic Clinical factors in Primary Uveal Melanoma
3.7.1. Size
Large studies have been published to detect prognostic factors in uveal melanoma patients.
The strongest clinically detectable unfavorable factor is the large size of the tumor.114;117
Although there is dispute about how the size should be measured – LBD, height, or volume –
it seems that LBD would have the strongest significance on prognosis.
3.7.2. Location
The location of primary tumor is an independent prognostic factor of survival.76 The
survival with ciliary body tumor is poor compared with choroidal tumor, or especially with
iris tumor which are small and metastasize extremely rarely.76 Anterior location of the
tumor,118 especially the location of the anterior margin of the tumor is associated with poor
survival.117
3.7.3. Gender
Male gender was an independent unfavorable factor with respect to time to systemic
metastases.114
3.7.4. The Growth Rate
A high growth rate of uveal melanoma predicts poor tumor related survival.24 The fast
shrinkage of the tumor after treatment may be a sign of rapid cell cycling and indicates
potentially highly malignant cell types and poor survival.8;11;56;74 Although the high growth
rate or fast cell cycling are not necessarily linked to dissemination capacity of the cells, these
patients seem to have worse survival prognosis than patients with slowly deteriorating tumors.
Contradictory results based on sarcomas have been presented which suggest that some
rapidly growing cancers are less radiation sensitive.138 The uveal melanoma metastases
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developing several years after primary tumor diagnosis are more likely to be associated with
slowly progressing tumors.128
3.7.5. Exudative retinal detachment
Exudative retinal detachment due to the tumor is associated with tumor size and
microvascular loops and networks but does not have independent prognostic significance on
survival after adjusting for these factors.72
3.7.6. Histologic and Cytologic factors
Even though the staining methods have developed and more accurate diagnosis and
prognosis could be established the clinical relevance of the pathologic findings of the primary
tumor has diminished because of irradiation treatments. Before irradiation, almost all eyes
were enucleated and pathological diagnosis was available. In case of secondary enucleation
after irradiation the tumor is usually degenerating and pathological analysis does not reflect
situation at diagnosis.
The tumors are categorized by their cell type by Callender classification and its later
versions; spindel cell, mixed cell, and epithelioid cell melanomas. The spindel cell melanomas
are slowly growing and have better survival prognosis than others. Epithelioid tumors seem to
grow faster and be more likely to metastasize.117
3.7.7. Microvascular patterns
Intratumor vascular architecture can be estimated with loops, nets, and networks formed by
extracellular vascular-like structures. Microvascular patterns of the primary tumor have been
studied by Folberg et al, Seregard et al, and Mäkitie et al and they have presented quite clearly
the independent prognostic significance of them.50;51;80
3.7.8. MVD
High microvascular density (MVD), a widely applied morphologic measure of
vascularization, independently predicts death in several types of cancer and has been linked to
shorter survival in uveal melanoma patients.52 In a multivariate analysis of uveal melanoma
specific survival study the MVD retained its value as independent predictor as did the
microvascular patterns.81
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3.7.9. Immunological factors
The late onset of metastatic disease could be explained partly by immunological factors.
The effect may be mediated by tumor infiltrating and circulating immune cells such as
lymphocytes and macrophages.39;81;148 Increase in the count of intratumor macrophages
predicts also unfavorable prognosis.81
Human leukocyte antigens (HLA) are essential for immune cells to recognize neoplastic
cells.79 Of HLA class I antigens, low expression of HLA-A and HLA-B antigens has been
associated with better survival.19;68
3.7.10. Cytogenetics
Although family history of uveal melanoma is very rare, a few cases may have an
inheritable component.42 Genetic predisposition has not been studied widely and no
concluding evidence of inherited genetic mutations that would increase risk for uveal
melanoma exists.
Genetic studies of tumor cells have identified loss of chromosome 3 as a sign of poor
survival.1;105;135;155 In addition loss of 6q, and gain of 8q were significantly associated with
poor overall survival.1;135 In contrast, in the study of White et al. patients having chromosome
6 abnormalities seemed to have longer survival.155 These findings concerning abnormalities in
chromosome 6 are preliminary and require further studies to solve these contradictory results.
3.8. METASTASES
The ability to metastasize is the main difference between benign and malignant tumors. A
benign tumor can eventually convert into a malignant one due to DNA changes in subclonal
cell lines. These changes in DNA might predispose tumor cells to other mutations and lead to
uncontrolled growth and invasion. The larger the tumor is, the more cell-cycles have taken
place and thus the risk for changes has increased. These changes may lead to more malignant
cell lines.
To disseminate malignant cells have to be able to infiltrate and invade surrounding tissues.
Malignant tumors can spread locally and disseminate via lymphatics and hematogenously to
distant locations depending on the type of cancer and the location of the primary tumor.
Most malignancies will develop metastatic tumors in characteristic locations and organs.
This can be anticipated and taken into account when treating patients. Breast cancer e.g.
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usually metastasizes to axillary lymph nodes and later to lungs and bone. When treating breast
cancer surgically at least sentinel nodes are removed for pathologic examinations.
Usually cancers that disseminate hematogenously develop metastases in lungs. Despite the
mechanical pressure and circulatory logic, cells of certain cancers such as uveal melanoma
seem to have a natural propensity to home themselves into other suitable locations such as the
liver.
3.8.1. Epidemiology of Disseminated Uveal Melanoma
Malignant melanoma of the uvea causes clinical metastases in one half of patients within
ten years.16;21;37;69;78 It is often a slowly growing, early metastasizing cancer. Diagnosis is
usually based on fine-needle aspiration biopsy (FNAB) or thru-cut biopsy, more so with
patients who are eligible for treatment. Other patients are diagnosed based on typical clinical
and imaging findings, progression, absence of any evidence of second cancer, and in few, not
earlier than at autopsy.
The metastases are diagnosed on average 2 to 5 years after primary tumor.58;60;114;159
3.8.2. Zimmermanns’ theorem and COMS
In 1978 Zimmermann and McLean postulated that the enucleation or some factor related to
it promotes dissemination of melanoma cells into the systemic circulation.92;159
They based their hypothesis on the finding that initially low mortality rises abruptly
following enucleation, reaching a peak by the second year.
They suspected that either the operation might interfere with the immune defense system
and lead to survival and accelerated growth of the disseminated cells or the mechanical stress
of the operation on the eye globe would enhance dissemination. Presumably, compression on
the globe during the enucleation procedure caused tumor cells to exit via the vortex veins,
thus causing metastasis.
In early 1980’s radiation therapy made its way into the everyday management of uveal
melanoma. Some clinicians still rigorously believed in the superiority of enucleation.84;86
Zimmermanns’ theorem was widely discussed and the question whether to treat patients with
enucleation or irradiation led to a massive clinical multicenter trial in USA. The Collaborative
Ocular Melanoma Study was launched. The patients were divided into three groups; small,
medium, and large tumors. Those with small tumors (up to 3 mm in elevation) were observed
for tumor growth; if growth was sufficient to place the tumor in the medium group and if the
patient remained eligible and willing, the eye was randomized for treatment. The two main
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questions of the study were: - would adjuvant external beam therapy be of benefit with
enucleation of large melanomas, – would iodine 125 brachytherapy versus enucleation of
medium melanomas be of benefit.36
The accrual of 1317 patients ran 11 years and the patients were followed up from 2 to 13
years.35;36 The preliminary results were published in 2001, and the survival did not differ
between the treatments.36 These results strengthen the idea of dissemination taking place
before the primary tumor is treated but they do not address the possibility of not treating.
3.8.3. Metastatic Behavior
The behavior of uveal melanoma differs greatly from that of its cousin, cutaneous
melanoma (melanoma of the skin). Cutaneous melanoma usually spreads to regional lymph
nodes, skin, lungs, bones, and in one fifth of cases into liver. As the uveal melanoma is
situated in the intraocular space which is devoid of lymphatics it disseminates solely
hematogenously and the regional lymph nodes are spared. Delayed dissemination is rather
frequent.21;37;69 Its propensity to disseminate first to the liver has been designated one of the
most unusual phenomena in tumor biology.44
Usually, hepatic metastases are initially present in 40 to 60% of patients with disseminated
uveal melanoma.17;21;44;58;90;110 Eventually the liver is involved in up to 95% of patients,
5;17;58;69;70;110;139;145 even though up to 50% have later developed also extrahepatic metastases,
most often in the lungs, bone, skin, and brain. 5;17;21;58;69;70;110;145
3.8.4. Metastatic Disease - Diagnosis
The diagnosis of metastatic uveal melanoma is usually suspected after imaging by chest
radiograms, abdominal ultrasonography (US), computed tomography (CT), and magnetic
resonance imaging (MRI) techniques. The diagnosis is based on FNAB or other tissue
specimen of the metastatic tumor in about 65% of cases.145 A post-mortem autopsy is rarely
performed. Whether the suspicion of metastatic disease has arisen because of symptoms such
as weight loss, abdominal complaints, or malaise or due to the screening examinations, the
patient is usually referred to a medical oncologist for evaluation of treatment.
3.8.5. Lead-time Bias
In cancer research, especially in treatment studies, overall survival is a key parameter
which refers to the time from diagnosis or treatment start to death. In fast progressing cancer
it is crucial when the diagnosis is made because a few months have a great effect on measured
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survival. This presents a problem in treatment trials of metastatic uveal melanoma. After the
primary tumor is treated the observed disease free time may be several years, but when the
metastases are detected the overall survival is typically counted in months.
To obtain an accurate estimate of the effect of a particular treatment for metastases the
patients should ideally be randomized or, failing that, be enrolled in similar condition or
categorized in corresponding groups. The former option requires constant and frequent
follow-up and the latter a way to reliably estimate the prognosis of an individual patient and
to stage the patient according to this prognosis. In this way, it is possible to differentiate
between the natural history of the disease and treatment effect.
3.8.6. Staging
TNM classification is a widely used staging method for various cancers. T refers to
primary tumor characteristics, N to the possible involvement of regional lymph nodes, and M
to systemic metastatic disease. Each of these indexes has its own numeral corresponding to
the extent of the clinical findings. Based on the TNM classification patients are staged into 4
stages ( I, II, III, IV). Each of these 4 stages may have subgroups e.g. (IIA, IIB, IIC). Stage
IVB corresponds metastatic uveal melanoma (as of January 2003; Stage IV in the new TNM
classification).137
Although it is uncommon to include serum factors, S-LD level considered with site(s) of
metastases has such prognostic value in evaluating patients suffering from stage IV cutaneous
melanoma, that they are subcategorized within the M categories into three groups by their S-
LD levels (M1a, M1b, and M1c; 1-year survival 59%, 57%, and 41%, respectively).14
3.8.7. Growth Rate
Understanding the kinetics of tumor growth is helpful in planning optimal treatment and
follow-up programs. A basic method to analyze tumor progression based on clinical data is
calculation of tumor doubling times.24;55;66;83;85;86;152 The concept of doubling times was
introduced by Collins in 1956,27 before which no quantitative measures of estimating tumor
growth were available. He drew attention to the presumably long asymptomatic period and
seemingly rapid growth when metastases become detectable, theorems which are still valid.
He also postulated that if the growth rate of a tumor is known, then the time when
micrometastasis occurred can be estimated.27 His calculations and deductions were based,
however, on the assumption of a constant exponential growth of primary tumors and their
metastases.27
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In fact, cancer cells undergo sequential mutations which often give rise to faster growing
subclones.74 Problems are created by changes in the shape of the tumor over time, apoptosis,
deficient blood supply, and by loss of cells due to immune defense and other host factors.151
Indeed, it has been definitively shown that neither primary tumors nor their metastases have
constant growth rates.74;104;151 This fact makes use of doubling times based on certain points in
their progress imprecise predictors of tumor behavior. Alternatively, Gompertzian growth
kinetics could be used in estimating tumor growth. It assumes that the growth rate slows as
the tumors increase in size. It is more accurate but also much more complicated.71 In spite of
these problems, exponential growth kinetics - doubling times provide an estimate of the
average growth rate during specified intervals, and such data can provide clinically useful
estimates for planning appropriate treatment and follow-up programs.
Limited information about doubling times of primary uveal melanomas is available, mainly
from small untreated tumors followed over time and from patients who refused
treatment.10;24;55 These times range from 60 to more than 4000 days, and it has been inferred
from epidemiological data that small melanomas might take an average of 7 years to grow
large.92 Only theoretical doubling times for metastatic uveal melanoma have been published.
These times are estimated to be comparable with the shortest doubling times of primary uveal
melanoma.85 The growth rate of detectable metastases is notably faster than that of the
primary tumors. Several factors could impede the growth rate and thus the progress of the
disease, such as overall health condition, age, other diseases, gender, and the treatments given.
Also, the nature of the metastatic tumor itself is one of the most important factors.
3.8.8. Screening Program
In the mid 1970's, it was suggested that patients with malignant uveal melanoma should be
screened for metastases.21;44;94 Clinical examination to detect hepatomegaly, liver function
tests (LFT), and chest x-ray were recommended annually, followed by liver imaging if
abnormal.21;44 It was, and still is, unclear what constitutes an adequate screening program,
however.21;114 Few papers devoted to the clinical and laboratory findings of patients with
metastatic uveal melanoma have been published since,6;21;37;38;45;94 and two major review
articles on the treatment of primary and metastatic uveal melanoma, respectively, do not
discuss screening at all.4;131 Only recently some articles have again emphasized and
recommended scheduled screening.114;145
North American centers mostly use clinical examination, LFTs, and chest x-ray for
screening,58;114;141;143 even though imaging of the liver as an additional measure has been
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recommended by investigators interested in metastatic melanoma.70;90;114 The time schedule of
the program is also unclear, most centers recommend annual screening, but in some centers
semiannual program is used114 In some countries, imaging of the liver has been routine for the
last decade.75;139 In others, however, screening is thought to be of no benefit, given the limited
impact on survival of current chemotherapy regimens.4;5;17;21;44;58;70;97;110
3.8.9. Adjuvant Therapy
The possible benefits of adjuvant therapy at the time of treatment of the primary tumors are
under investigation. In 1990, the Bacillus-Calmette vaccination was used to enhance the
immune system to fight cancerous cells but it did not show any effect.90 DTIC has been tried
as an adjuvant therapy but the results have not been published. EORTC has recently launched
a study were cutaneous melanoma and uveal melanoma patients are administered a
vaccination program where the immune system is sensitized against certain antigens common
in uveal melanoma cells. The results are expected after 2 years of enrollment and 5 years of
follow-up, around 2009.
3.8.10. Treatment
Recently, a shift of emphasis from palliative chemotherapy given on an individual basis4;5
to controlled clinical trials in centers treating metastatic uveal melanoma has taken place.75;97
Current chemoimmunotherapy regimens have provided few objective responses and no long-
term cures. 4;5;17;21;44;58;70;75;97;106;110
One of the chemoimmunotherapy regimens used in Finland is a combination of bleomycin,
vincristine, lomustine, dacarbazine (BOLD) with intercycle alpha interferon-2b. It has been
considered active in the treatment of metastatic uveal melanoma but recent results are not
encouraging.97;108 Among twenty evaluable patients, four objective responses were observed
(RR = 20%).97
Surgery is pursued in some cases with solitary metastasis with good results in carefully
selected patients. The median survival has reached more than 22 months.43;113 Palliative
radiotherapy is also used, more so in extrahepatic tumors.
Given the rarity of objective responses that can be imaged and measured in longer survival
and the possibility of lead-time bias in median survival, tumor doubling times might provide
an additional criterion for comparing systemic treatment responses in metastatic uveal
melanoma.
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4. AIMS OF THE PRESENT STUDY
The purpose of this study was to:
1. Enlighten the prognostic significance of factors related to the screening program of
patients with uveal melanoma.
2. Present an estimate of the possible lead time bias of survival in treatment trials.
3. Develop a working formulation for staging patients into subcategories according to their
predicted survival.
4. Estimate the time of dissemination based on the doubling times of the metastatic
tumors.
5. Evaluate the sensitivity of various screening tests routinely used in our institution, the
time schedule and overall yield of our screening program.
6. Identify delays in the chain of treatment before treatment of the primary uveal
melanoma
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5. PATIENTS AND METHODS
5.1. Eligibility criteria and enrolment
All enrolled patients had had unilateral melanoma of the uvea. Patients were ascertained
according to regimens of each study design from the registry of the Helsinki University
Central Hospital, which is a tertiary referral unit that manages over 90% of uveal melanoma
patients in Finland. All four studies are retrospective cross sectional studies by design (Fig.1).
They were approved by the Institutional Review Board and followed tenets of the Helsinki
Declaration.
Fig.1. Diagram showing overlapping of the cohorts of
the four studies. The patients in the three first studies (I;
46, II; 37, III; 91) all had metastatic disease and most of
them had already died by the time of the study. Death
was a prerequisite in the third study (III). The patients in
the fourth publication (IV; 159) were alive without
metastases. The paradoxical overlapping is due to
different timing of the four studies and to the fact that
they are not numbered chronologically.
5.1.1. Screening for Metastatic Malignant Melanoma of the Uvea (I)
Entry criteria were development of metastases from malignant melanoma of the uvea and
regular participation in an annual screening program to detect such metastases allowing for
one missed visit. A total of 62 consecutive patients who had been diagnosed to have
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developed metastatic uveal melanoma between January 1985 and December 1996 were
ascertained.
Of the 62 patients, 46 (74%) fulfilled both inclusion criteria. The mean age at diagnosis of
metastatic malignant melanoma of the uvea in the 46 patients was 63 years (range, 23 to 86).
The diagnosis of metastatic uveal melanoma was histopathologically verified in 30 of them
(65%). In the remaining 16 patients (35%), the diagnosis was based on typical clinical and
imaging findings, progression, and absence of any evidence of second cancer. Because many
of the latter patients were not willing or ultimately eligible to receive active treatment,
histopathologic confirmation had not been pursued.
In 3 of the 16 ineligible patients, the diagnosis of disseminated uveal melanoma was
proved wrong, and 13 patients had not participated in the screening program.
5.1.2. Tumor Doubling Times in Metastatic Malignant Melanoma of the Uvea (II)
Entry criteria were 1.) diagnosis of metastatic malignant melanoma of the choroid and
ciliary body between August 1986 and April 1998, 2.) participation in an annual screening
program to detect such metastases, 3.) availability of imaging data from a prior screening
examination performed within 15 months before the diagnosis of metastases, and 4.)
availability of US or CT scans with measurable metastases at diagnosis of disseminated
disease.
 A total of 70 consecutive patients were diagnosed to have metastatic uveal melanoma. Of
these 70 patients, 37 (53%) fulfilled all four inclusion criteria and were enrolled. Their mean
age was 61 (range, 23 to 86). Of 33 excluded patients, 7 (10%) had not participated in the
screening program, 10 (14%) had missed the previous screening examination, 11 (16%) had
imaging data that did not allow accurate measurements, and 5 (7%) had been followed up
with liver isotope scanning rather than with US or CT.
Diagnosis of disseminated melanoma was confirmed by histopathology in 26 patients
(70%). The remaining patients (30%), many of whom were not candidates for
chemoimmunotherapy, were diagnosed on the basis of clinical findings and imaging data. Of
the 37 patients, 30 (81%) were treated with chemotherapy or chemoimmunotherapy, most
often combination chemotherapy with bleomycin, vincristine, lomustine and dacarbazine
(BOLD) with interferon97;107 that was given to 23 of the 30 (77%) patients. Subsequent
imaging data during therapy were available from 23 of the 30 treated patients (77%).
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5.1.3. A Prognostic Model and Staging for Metastatic Uveal Melanoma (III)
Entry criterion was death of metastatic malignant uveal melanoma between January 1985
and December 2000. A total of 99 consecutive patients who had been suspected of dying of
metastases were ascertained from the registry.
Of the 99 patients, 95 (96%) fulfilled the inclusion criteria. The diagnosis of metastatic
uveal melanoma was confirmed by cytology or histology in 59 (62%) of them. The diagnosis
of the remaining 36 patients (38%), most of whom were not candidates for systemic
chemotherapy, was based on typical clinical and imaging findings, progression, and absence
of any evidence of second cancer
The suspected metastases of the 4 ineligible patients proved to be unrelated to uveal
melanoma.
One eligible patient whose metastases were first diagnosed at autopsy and 3 patients whose
charts on treatment of metastases were unavailable were excluded from the analysis, leaving
91 patients in the study (inclusion ratio, 96%). Their mean age was 62 years (range, 23y to
86y).
5.1.4. Mode of Presentation and Time to Treatment of Uveal Melanoma in Finland (IV)
All consecutive patients with primary malignant melanoma of the uvea diagnosed between
July 1994 and June 1999 were eligible. Of the 184 eligible patients, 10 (5%) had died of
various reasons and 15 (8%) of them could not be contacted. All 159 patients contacted
consented to the study and underwent a structured telephone interview (inclusion rate, 86%).
Their mean age at the time of diagnosis of primary uveal melanoma was 60 years (range, 14-
87).
5.2. Data Collection
5.2.1. Clinical Data Collection
The date of the diagnosis of primary uveal melanoma and the date of the diagnosis of
metastatic tumor were taken from patient charts, and relapse-free interval was calculated as
the difference between the two dates. In addition, the age and gender of the patient, Karnofsky
index, symptoms from metastases, and the duration of these symptoms were recorded (I - III).
Karnofsky index is a measure to categorize patients’ overall health condition.
In addition, the time on chemotherapy was calculated as the interval from the date of the
first cycle to that of the last. (III)
Patients and Methods
31
The dates of all visits to a dispensing optician, a physician other than an ophthalmologist,
an ophthalmologist, and the ocular oncology service were determined by structured interview
and verified, whenever possible, from patient charts, bills, and other legal documents. The
reason for each appointment was identified. (IV) The date of diagnosis of primary tumor, the
tumor height and diameter, and the date and type of treatment were obtained from patient
charts. If the patient had been screened because of a presumed intraocular nevus, the charts
were obtained from the practitioner in question. (IV)
5.2.2. Liver Function Tests
The levels of AST, ALT, AP, and LD at the time of diagnosis of metastases and at the two
preceding screening examinations were recorded from the patient charts. (I, III) The latter had
taken place one and two years before, except when metastases were diagnosed on the basis of
symptoms or one screening visit had been missed.
5.2.3. Imaging Data
The original x-rays, liver isotope scans, printouts of ultrasound examinations, and CT
scans were reviewed. (I - III) Largest perpendicular diameters of all metastases were
measured using a lightbox and a caliper. For US examinations, measurements were also taken
from the original reports.
5.2.4.Tumor volume
5.2.4.1. Primary tumor volume
The height and the largest basal diameter of the primary intraocular melanoma were taken
from the patient chart and printouts of US examinations. For calculation of the volume of the
primary tumor, an equation based on ellipsoidal forms was used, (II)24;55:
(1)    2**
6
lbdhVprim
π
=
where h is the height and lbd is the largest basal diameter of the primary intraocular
melanoma in millimeters.
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5.2.4.2. Metastatic volume
The hepatic, extrahepatic and total metastatic burden was estimated as the sum of the
product of the largest perpendicular dimensions, multiplied by their mean, of measurable
metastases. (I – III)
5.2.5. Estimation of Doubling Times
The measurements originated from imaging studies performed at diagnosis of metastatic
disease and at follow-up visits during active treatment for metastases. (II)
For calculating tumor doubling times, the equation of Schwartz was used:116
(2)     )/log(*10 01 DD
tDT =
where t is the time between measurements, D0 is the diameter of the metastasis at baseline,
and D1 the diameter after time t. Whenever possible, the doubling times were calculated as the
mean for the three largest metastases to lessen the effect of variable growth rates and
inception times of individual metastases.66;66;151
When analyzing the growth of metastases at diagnosis, t was the interval between the first
positive and the last negative scan. The assumption was made that the metastasis was present
but below detection threshold when the scan had been negative.152 A liver metastasis that is
10 mm in diameter is more likely than not to be visible by routine US and CT, and is already
suitable for FNAB.93 The smallest metastases actually detected were 4 to 6 mm in diameter.
In most calculations, we presumed that D0 was 6 mm for all metastases. As a sensitivity
analysis, alternative values of 4 mm and 8 mm were used.
When analyzing the growth of metastases during active treatment for metastatic uveal
melanoma, the average tumor doubling times during treatment were directly calculated from
the diameters of metastases measured at diagnosis and at the end of active therapy. In these
calculations, t was the time between the diagnosis of metastases and the last screening scan,
and D0 and D1 were the means of the largest perpendicular diameters of metastases at
diagnosis and at last screening, respectively.
To estimate the time of initial micrometastasis the following equations were used:
(3) NVV 2*01 =
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(4) DTNT *=
where V0 is volume of a single tumor cell, V1 is volume of the metastasis at diagnosis, N is the
number of cell divisions, T is time from micrometastasis to diagnosis of disseminated disease,
and DT is the tumor doubling time. By solving for N we obtain:
(5) DT
V
V
T *
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To get V0, diameters of 35 epithelioid uveal melanoma cells were measured. Presuming
them to be spherical in shape, a value of 4*10-6 mm3 was obtained. V1 was calculated as the
product of the largest perpendicular diameters multiplied by their mean. The calculation was
carried out alternatively by using the doubling time calculated for the largest metastasis and
by using the mean doubling time calculated for up to three largest metastases.
These calculations are based on constant exponential growth.27 Actually, tumors may
accelerate growth before becoming clinically detectable and they may decelerate growth once
metastases are bulky.104
5.3. Statistical Methods and Data Analysis
5.3.1. General guidelines (I - IV)
 The data were collected and analyzed using the database and statistical software packages
Dbase4 (Ashton-Tate Corporation, UK), BMDP PC-90 (BMDP Statistical Software, Cork,
Ireland), GraphPad Prism 2.01 (3.01) (GraphPad Software, San Diego, CA, USA), Microsoft
Access, SPSS for Windows 9.0.1 (SPSS Inc.), Power and Precision 2 (Biostat, Englewood,
NJ), and Stata 7.0 (Stata Corporation, College Station, TX).
The mean and standard deviation are given for normally distributed variables, and median
and range for other variables. The 95 % confidence intervals (CI) were calculated for main
findings.27 Normally distributed variables were compared with Student's t-test, other
continuous variables with Mann-Whitney's U-test, Kruskal-Wallis test, and their
interrelationships were analyzed with Spearman’s rank correlation. Fisher's exact test and
Pearson’s χ2 test were used to compare unordered contingency tables.
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5.3.2. Analysis of doubling times (II)
To estimate the range of the doubling times, the doubling times calculated for each patient
were plotted, ordering them from shortest to longest based on the default sensitivity limit of
6mm. Three different values for the sensitivity of imaging to detect metastases at screening
were used. To find out if large size of primary tumors and metastases was associated with
more rapidly growing metastases, the doubling times were plotted against the height, largest
basal diameter, and volume of the primary tumor, and against the largest diameter of the
largest metastasis. To find out whether long disease-free intervals were associated with more
slowly growing metastases, the doubling times were plotted against the observed relapse-free
interval. Association between the variables above was assessed using Spearman’s rank
correlation coefficient. To gain an insight into the time of initial micrometastasis relative to
the treatment of the primary tumor, the difference between the observed relapse-free interval
and the calculated estimates of the time of micrometastasis was plotted against the observed
relapse-free interval. To asses the effect of treatment on growth of metastases that did not
show an objective response, the mean doubling time at the time of diagnosis of disseminated
disease and during treatment were plotted against each other for all patients whose metastases
continued to grow.
5.3.3. Survival analysis (III)
5.3.3.1. Kaplan-Meier method
Survival analysis was based on Kaplan-Meier product limit method, and melanoma-
specific survival was compared with the log-rank test that gives equal weight to the entire
survival curve. Test for linear trend was used if categories analyzed were ordered. For
analysis, age at diagnosis, the largest dimension of the largest metastasis, metastatic burden,
and serum LFT levels were divided into tertiles. Alternatively, LFTs were categorized relative
to the upper normal limit (< 1X UNL, 1-2.5X UNL, >2.5X UNL). The performance status
was categorized into three groups: essentially asymptomatic patients (Karnofsky index 100 to
90 [equivalent to ECOG performance status98 0]), symptomatic patients (Karnofsky index 80
to 60 [ECOG 1-2]), and symptomatic patients generally not fit for chemoimmunotherapy
(Karnofsky index 50 or less [ECOG 3-4]). Differences between unordered and ordered
categories were assessed by the log-rank test and test for trend.
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5.3.3.2. Cox multiple hazard regression
Cox proportional hazards regression was used to adjust survival time data for the effect of
confounding factors146 and to identify independent predictors of prognosis. Age at diagnosis,
the largest dimension of the largest metastasis, metastatic burden, and serum levels of LFTs
were modeled as continuous variables. The assumption of proportional hazards was tested by
the method of Therneau and Grambsch.146 Independent variables were allowed in the model if
P < .10 and confounding variables were kept in the model irrespective of statistical
significance.63 Regression coefficients and hazard ratios (HR) with 95% confidence intervals
(CI) were calculated. Power analysis indicated that the present study had an 80% power to
detect a HR of 1.8 and 95% power to detect a HR of 2.2 as significant.
Time on chemotherapy was modeled as a confounding variable. The number of variables
in the final model was restricted to four, based on a rule that at least 15 to 20 events are
required per variable.101
5.3.3.3. Working formulation for predicted survival with metastatic uveal melanoma
The coefficients were entered into the general Cox model, and the predicted median
survival time was calculated from adjusted survival curves for a variety of clinically relevant
combinations of covariates. Uveal melanoma regional lymph node and systemic metastases
are currently categorized as stage IVB (as of January 2003; stage IV).136;137 Based on
predicted survival, three subcategories for stage IVB were formulated: median survival in
excess of 12 months (stage IVBa), median survival from 6 to 11 months (stage IVBb), and
median survival less than 6 months (stage IVBc). Thereafter, patients were staged according
to the working formulation, and the observed survival for each category was plotted by the
Kaplan-Meier product-limit method and compared with the log-rank test for trend.
5.3.4. Analysis of delay times (IV)
To compare delay times, cumulative frequency distribution plots for time from initial
presentation of the tumor to treatment planning and to treatment at the ocular oncology
service were also drawn making it possible to determine by which time any specified
proportion of patients was attended. The tumors were categorized as: small if they were less
than 10.5 mm wide in their LBD and less than 2.5 mm in height; medium if LBD was
between 10.5 mm and 15.4 mm or the height was between 2.5 mm and 8.4 mm; and large if
LBD or height exceeded these figures.31
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6. RESULTS AND DISCUSSION
6.1. SCREENING FOR METASTATIC MALIGNANT MELANOMA OF THE
UVEA (I)
Because of the wish to detect patients with metastases at a sufficiently early stage to allow
chemotherapy or surgery, there is now a need to critically evaluate the usefulness of
noninvasive screening procedures in detecting metastases from malignant uveal melanoma.
This uncertainty and lack of data are reflected in great differences in current screening
programs worldwide.
6.1.1. Diagnosis of metastases
The mean age at diagnosis of metastatic malignant melanoma of the uvea in the 46 patients
was 63 y (SD, 13; range, 23 to 86). Their median relapse-free interval was 2.2 y ranging from
4 months to 6 years 11 months. Altogether 27 patients were entirely asymptomatic and 19
patients had symptoms when metastases were diagnosed (Table 2). In 34 patients (74%; 95%
CI, 59 to 86), metastatic uveal melanoma was diagnosed at a scheduled screening
examination, irrespective of recent onset of symptoms in 7 patients (15%; 95% CI, 6-29) who
had a skin nodule or abdominal complains (Table 2).In 12 patients (26%; 95% CI, 14 to 41),
signs or symptoms of metastases led to the diagnosis before the next scheduled screening visit
(Table 2). The median interval from the preceding visit was 10.7 months (range, 5 months to
2 years 2 months); 1 patient presented within 6 months after previous screening, 9 patients
within 6 months before the next screening, and 2 patients had missed the immediately
preceding screening visit. The median relapse-free intervals of patients whose metastases
were diagnosed at screening and on the basis of symptoms (2.2 v 2.0 y; P = .28, Mann-
Whitney U-test) or those of asymptomatic and all symptomatic patients (2.2 v 2.1 y; P = .26)
did not differ.
Of the 46 patients in our screening program, 59% were without symptoms when metastases
were detected. The diagnosis was made earlier than in the case if they had not been screened.
In 74% the diagnosis was made at a scheduled screening visit. Seven patients (15%) who had
symptoms but were diagnosed at screening may have waited for the forthcoming visit instead
of consulting their physician, and hence may have had the diagnosis delayed. Their screening
results resembled more of the asymptomatic patients’ results detected at screening than those
diagnosed on the basis of symptoms before the next scheduled visit.
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6.1.2. Sites of metastases
In 37 patients (80%; 95% CI, 66 to 91), only hepatic metastases were detected; they were
multiple in 22 patients. Two patients had only extrahepatic metastases, and 7 had hepatic and
extrahepatic lesions (Table 3). All 34 patients (100%; 95% CI, 90 to 100) who were diagnosed
at screening had hepatic metastases; 3 (9%) also had extrahepatic metastases (Table 3). In
particular, all asymptomatic patients had hepatic metastases, and two had pulmonary
metastases. Out of 12 patients diagnosed on the basis of symptoms, liver metastases were
found in 10; 6 (50%) also had extrahepatic ones. Of 31 patients who had no weight loss or
abdominal complains, 30 (97%; 95% CI, 83-100) had hepatic metastases. In 80% of 46
patients (95% CI, 66 to 91), only liver metastases were detected. Only 2 (4%, 95% CI, 1-15)
of our 46 patients had pulmonary metastases at diagnosis.
These findings are in line with previous studies. Traditionally, hepatic metastases are
initially present in over 40 to 60% of patients.17;21;44;58;90;110 Eventually the liver is affected in
up to 95% of patients, 5;17;58;69;70;110;139;145 even though up to 50% later also have extrahepatic
metastases, most often in the lungs, bone, skin, and brain. 5;17;21;58;69;70;110;145
6.1.3. Metastatic burden
The median size of the largest metastasis of 38 patients with measurable lesions was 4.8
cm (range; 1.0 to 30.0). The median total, hepatic, and extrahepatic burden of metastasis was
102 cm3 (range; 1.2 to 6050), 95 cm3 (range; 0 to 6050), and 0 cm3 (range; 0 to 103),
respectively. The median size of the largest measurable metastasis of patients diagnosed at
screening and on the basis of symptoms did not differ (4.5 v 5.2 cm; P = .96, Mann-Whitney
U-test). Their total (104 v 71 cm3; P = 1.00) and hepatic metastatic burdens (98 v 39 cm3; P =
.82) were also comparable. These three parameters were similar also between asymptomatic
and all symptomatic patients (5.0 v 4.0 cm, P = .51; 112 v 38 cm3, P = .33; and 109 v 38 cm2,
P = .31, respectively).
The fact that the median size of largest metastasis, tumor burden, and disease-free interval
of patients who did or did not have symptoms were overlapping suggests that some patients
are more likely to have symptoms than others, perhaps based on the growth rate and location
of the metastases.
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6.1.4. Liver Function Tests
At least one LFT was abnormal in 32 patients (70%; 95% CI, 54 - 82). Such a finding was
equally frequent in patients whose metastases were diagnosed at screening and on the basis of
symptoms (65% v 83%, P = .29, Fisher's exact test), as well as in patients who had or did not
have symptoms attributable to hepatic metastases (80% v 65%, P = .33). The overall
sensitivity of AST, ALT and AP ranged from 0.27 to 0.43, whereas that of LD was 0.67
(Table 4). The specificity of all LFTs ranged from 0.90 to 0.96 (Table 4). LD had the greatest
likelihood ratio for a positive and a negative test (Table 4).
Patients whose metastases were detected due to symptoms rather than at screening had more
often an elevated AP level (P = .004, Fisher's exact test), and their median AST (P = .01,
Mann-Whitney U-test) and AP (P = .001) was higher (Table 5; Figure 1). The sample size of
LD was too small for subgroup comparison. The median LFT levels of asymptomatic patients
did not differ from those of all patients diagnosed at screening (Table 5).
TABLE 4. Sensitivity (true positive rate), specificity (true negative rate), and likelihood ratios
of liver function tests in detecting metastatic uveal melanoma.*
Likelihood ratio
Enzyme Criteria Sensitivity Specificity Positive test† Negative test
AST
Above normal value 0.43 0.93  5.8 0.62
1.2 X higher 0.63 0.73  2.3 0.52
ALT
Above normal value 0.38 0.90  3.8 0.68
1.2 X higher 0.66 0.65  1.9 0.52
AP
Above normal value 0.27 0.95  5.0 0.77
1.2 X higher 0.49 0.92  6.3 0.55
LD
Above normal value 0.67 0.96 14.7 0.35
1.2 X higher 0.65 0.71  2.3 0.49
* Based on data from 46 patients with and 325 patients without metastatic uveal melanoma.
† The false positive rate can be calculated as 1-specificity.
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The sensitivity of observing a 20% increase in LFT levels ranged from 0.49 to 0.65, and
the specificity of these tests ranged from 0.65 to 0.92 (Table 4). Increase in the level of AST
(P = .025, Mann-Whitney U-test), ALT (P = .016), and AP (P = .006), as compared with the
level at the preceding screening examination, was greater in patients whose metastases were
diagnosed on the basis of symptoms rather than at screening (Table 5). This difference was
smaller when asymptomatic patients were compared with all symptomatic patients (Table 5).
LFTs are used for screening of hepatic metastases of skin and uveal
melanoma.6;17;21;37;38;45;47;58;90;94;114 A set of four liver enzymes identified 70% of our patients
with metastases, including 2 patients who had a falsely negative abdominal US. The
specificity of all four LFTs among the selected, predominantly elderly patients screened was
high, translating to a false positive rate of 10% or less. In line with other studies, LD was the
most efficient LFT.16;22;38 As estimated from our data set, the post-test likelihood of a patient
having hepatic metastases is more than 14 times higher if LD is elevated. Thus, liver function
tests may provide useful additional evidence to supplement US findings when the latter are
unclear. Elevated LD may and AP seems to have prognostic significance in metastatic uveal
melanoma.(III)16;75 Gamma glutamyl transpeptidase (GGT) is probably similar to LD in
sensitivity and prognostic value.75
AST and ALT performed less well as individual tests, as expected on account of previous
studies.16;22;38 Nevertheless, some of our patients with hepatic metastases had only an elevated
AST, ALT, or both. They cannot be completely dismissed as screening tests.
This study also evaluated whether observing a specified increase compared with preceding
enzyme levels might be a sensitive test to identify hepatic metastases. The optimal cutpoints
were determined by plotting ROC curves.112 Even though the sensitivity of noting a specified
increase was higher for AST, ALT, and AP, the difference was not marked, and the specificity
and likelihood ratios were worse, except for AP.
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6.1.5. Imaging Studies
Abdominal US revealed unequivocal hepatic metastases in 36 patients (78%; 95% CI, 64 -
89). In 12 of them (33%; 95% CI, 19 - 51), all LFTs done were within normal limits. US was
suggestive of metastases in 5 additional patients (11%; 95% CI, 4 - 24), all of whom were
confirmed to have hepatic metastases by FNAB, CT, or both. US was negative in 2 patients
(4%; 95% CI, 1 - 15), both of whom had liver metastases and at least one abnormal LFT.
Three patients (7%) were not imaged. Only one patient (2%; 95% CI, 0-12) had a metastasis
in lung that was diagnosed in a screening chest x-ray; she had concurrent positive abdominal
US. Chest x-ray was negative in 39 patients (85%; 95% CI, 71-94), and suggestive of
metastasis in 5 patients (11%; 95% CI, 4 - 24). Pulmonary metastases were confirmed by CT
scan in only one of the latter five patients; this patient also had coexisting liver metastases by
abdominal US. CT scans were used in 24 patients (52%) to confirm metastases suspected at
screening, and as an additional staging examination when metastases had already been
diagnosed by other methods. In 17 of 19 patients (89%; 95% CI, 67 - 99), CT scan and US
were in agreement, but in two patients (11%; 95% CI, 1 - 33) either CT or US failed to show
hepatic metastases seen by the other method.
Abdominal US revealed definite metastases or led to a diagnostic CT, FNAB, or both in
89% of patients. In 33% of these 46 patients, all LFTs done were normal. Conversely, in 4%
of patients with liver metastases, US was normal whereas at least one LFT was elevated.
CT and MRI scans, not used primarily in our screening program, may be even more
sensitive than US in detecting hepatic metastases from uveal melanoma. In a previous study,
of 30 metastases identified in 4 patients at surgery, US detected 37%, MRI 67%, and CT
77%.75 The most sensitive imaging method was CT combined with arterial portography.
Obviously, it can only be used in staging and it is not ideal for screening.
These figures compare favorably with screening programs which used liver imaging only if
symptoms, abnormal physical examination, or LFTs indicated them. In a large study by
Gragoudas,58 30% of 145 patients (95% CI, 23 - 39) were asymptomatic, metastases involved
only the liver in 56% of them (95% CI, 47 - 67), and the frequency of a positive chest x-ray
was 24% (95% CI, 17 - 32). The frequency of pulmonary metastases in earlier smaller series
likewise ranged from 17% to 28%.17;37;110
Not counting the initial work-up radiograms, a total of 143 negative screening chest x-rays
had been performed to the 46 present patients who developed metastases. During the study
period, those 344 patients who did not develop metastases were subjected to more than 900
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chest x-rays, and some of them were screened for more than a decade. This study concludes
that the yield of a chest x-ray, widely used as the primary imaging test, is very low if
abdominal imaging is part of the screening program. At HUCH we have abandoned chest x-
ray as a screening examination in spite of rare cases of pulmonary metastases from uveal
melanoma.64;111;145;147 We still consider chest x-ray obligatory in the initial work-up to exclude
the possibility that the uveal tumor is a metastasis since both lung cancer and pulmonary
metastases are common in patients with cancer metastatic to the eye.46 It is also useful in
examining patients who develop pulmonary symptoms, and as a staging examination when
metastases are detected elsewhere.
6.1.6. Limitations
The main limitations of the first study (I) were retrospective collection of data and small
sample size. However, most data collected were dates and laboratory results from patient
charts, which leave little chance for error. Measurements of metastatic tumors could have
been more precise in a prospective study and recording of symptoms would have been more
accurate.
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6.2. TUMOR DOUBLING TIMES IN METASTATIC MALIGNANT MELANOMA
OF THE UVEA (II)
6.2.1. Tumor Doubling Times of Metastatic Uveal Melanoma at Diagnosis
The median interval from preceding negative screening imaging to detection of metastasis
was 12 months (range, 4 - 14).
The tumor doubling times based on three different assumptions about the sensitivity of
imaging to detect small metastases and on up to three largest metastases detected at screening
ranged from 34 to 220 days (Fig.2). The corresponding median doubling times calculated for
the single largest metastasis and for up to three largest metastases are summarized in Table 6.
Irrespective of the sensitivity limit used in calculation, the fastest growing third of metastases
gave doubling times between 30 and 70 days, and the intermediate third gave doubling times
between 40 and 120 days. Among the remaining third, the doubling times heavily depended
on the presumed sensitivity limit used in calculation, due to the fact that the smallest
metastases were of the same size range (or even smaller) than the limit used. Based on the
default limit of 6 mm of this study, two thirds of metastases had a doubling time between 30
and 80 days.
In 1980, Manschot claimed that doubling times of metastatic uveal melanoma tumors
would resemble those of fastest growing primaries, which range from 60 to 120 days.85;86
These figures are in the same range as was calculated in this study, but somewhat longer.
The calculated mean tumor doubling times did not differ between asymptomatic and
symptomatic patients (P = .43, Mann-Whitney U-test) or between patients who had or had not
symptoms of liver metastasis (P = .51). Tumor doubling times were statistically significantly
shorter in women as compared with men (median 50 vs. 72 days, P = .016).
The calculated mean doubling time and the largest basal diameter (P=.37, Spearman’s rank
correlation), height (P=.59), and estimated volume (P=.22, Fig.3A) of the primary intraocular
melanoma were not statistically significantly correlated with each other. Regardless of the
volume of the primary tumor, estimated mean doubling times clustered between 40 and 100
days (Fig.3A).
As compared with reported doubling times of primary uveal melanoma, which ranged from
71 to 540 days (median, 292) for spindle cell tumors and from 23 to 288 days (median, 128)
for mixed cell tumors,10 the data of this study (II) support the view that many uveal
melanomas accelerate growth with progression.85;86
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Fig.2. Sensitivity analysis of tumor doubling times calculated as a mean for up to three largest metastases
quantitating uncertainty in the estimates. The calculations were based on three hypothetical sizes of metastases at
latest negative imaging, 8 mm (downward pointing triangle), 6 mm (solid circle), and 4 mm (upward pointing
triangle). The patients were arranged in ascending order of doubling times calculated using the default limit of 6
mm. For an individual patient, the three estimates may change order because some of their metastases were
smaller than the limit used in a particular calculation.
Because previous estimates are based predominantly on patients who had small tumors,
they are not directly comparable with the range of primary tumors in our series. The fact that
the disease-free interval did not correlate with the doubling times of metastases would be
consistent with accelerated growth rates. Neither did we observe correlation between the size
of the primary tumor and doubling times of their metastases, even though the doubling time of
primary tumors has been shown to correlate with tumor size.27
The calculated mean doubling times were inversely related to the size of the largest
metastasis. When considering the asymptomatic patients, this is directly due to the data
collection method. When the diameter of the largest metastasis was 50 mm or more, the
doubling time was in each case 50 days or less.
A plot of the mean doubling time against the observed disease-free interval did not reveal
any obvious relationship between them (Fig.3B). Regardless of the length of the disease-free
interval, most doubling times clustered between 40 and 80 days, and surprisingly the longest
doubling times were associated with short and intermediate disease-free intervals rather than
long ones (Fig.3B).
The calculated doubling times were used to roughly extrapolate the behavior of the
metastases in the period prior to diagnosis.24;27;66;152 A plot of the observed disease-free
interval against the calculated time of micrometastasis relative to the time of treatment of the
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primary tumor showed that most of the primary tumors, assuming a constant growth rate,
would have disseminated within five years before primary treatment (Fig.4). The median
interval between the calculated dissemination and the treatment of the primary tumor
according to the doubling time of the largest metastasis was 1.9 years (range, 15.5 years
before treatment to 4.5 years after). The median interval according to the mean doubling time
of up to three largest metastases was 2.9 years (range, 15.5 years before treatment to 2.9 years
after).
Table 6. Tumor doubling times of metastatic uveal melanoma calculated on the basis of the
single largest metastasis and up to three largest metastases
      Tumor Doubling Time (days)___
Sensitivity         Largest Metastasis______       Three Largest Metastases___
level of
imaging (mm) Median (range) Mean (SD) Median (range) Mean (SD)
4 41 (17-110)  41 (16) 44 (29-120)  51 (21)
6 53 (23-220)  57 (37) 63 (34-220)  74 (42)
8 61 (27-123)  61 (26) 70 (29-207)  81 (41)
This information of growth can be used to position point A relative to the time of diagnosis
of the primary in following figure 5 (Fig.5). Moreover, the growth of metastases should
continue 2.2 years beyond the time of diagnosis, which was our observed median interval
from diagnosis of the primary tumor to diagnosis of metastases (range, 0.33-9.1). Adding
these two figures together we get an estimate of 5.1 years for AC, time to clinical metastasis
(Fig.5).
These data support the idea, which is also supported by similar survival after enucleation
and radiotherapy of uveal melanoma, that in majority of cases dissemination has already taken
place before treatment of the primary tumor, rather than at the time of or after
treatment.7;33;62;86;129 This is consistent with the theorem of Collins who suggested that half of
the whole life span of a malignant tumor occurs in a period of undetected growth prior to the
earliest possible sign or symptom.27 Because most patients were treated for their metastases, it
was not possible to study the association of initial tumor doubling times and eventual
survival.
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Fig.3. Association between tumor characteristics and mean tumor doubling time calculated for up to three largest
metastases. A) The volume of the primary intraocular melanoma did not significantly correlate with doubling
time of metastases. The line shows a linear regression fit with 95% confidence intervals. (B) The observed
disease-free interval did not correlate with doubling time of metastases.
In figure 5, we have plotted the time lines for primary and metastatic tumors separately.
The latter line extends from point A to the observed median volume of clinically diagnosed
metastasis at point C, which was 17 000 mm3 (Fig.5). Incidentally, this is equivalent to 32
tumor doublings and corresponds to a slightly shorter doubling time than the median. The
graph predicts that the volume of a metastasis at the time of diagnosis of the primary tumor
would be on average 0.5 mm3. Such tiny metastases would not be found by current diagnostic
methods, which is in line with the clinical experience that detectable metastases at baseline
are rare in uveal melanoma. It can now be estimated that at micrometastasis the primary
tumor would be on average 7 mm3 in size, which roughly corresponds to a dome-shaped
tumor 3.0 mm in diameter and 1.5 mm in height. This would still be a small tumor, but one
that should easily be detected by ophthalmoscopy.
We estimated that tumor doubling times of metastases are more likely to be biased towards
too long than too short times. If the median would be shorter than here estimated, the interval
AC would be shorter and the primary tumor even bigger at the time of micrometastasis.
The tumor doubling times of three patients whose metastases were diagnosed as late as 4 to
9 years after treatment of the primary tumor ranged from 45 to 70 days. Their observed
disease-free interval was longer than the extrapolated time from metastasis. These tumors had
been treated with brachytherapy, and hence it is possible that they metastasized 1 to 4 years
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Fig.4. The predicted time of initial micrometastasis
relative to the time of treatment (dashed line) of the
primary intraocular tumor plotted against the
observed disease-free interval. Doubling times were
based on the single largest metastasis (triangles) and
on up to three largest metastases (circles). Patients
who were treated for local recurrence of primary
tumor (solid circles and triangles) and those who had
no such recurrence (open circles and triangles) are
shown separately. In two thirds of patients the
primary tumor had predictably disseminated between
1 and 5 years before conservative treatment.
after treatment, especially the one that relapsed locally. Alternatively, these metastases could
have been initially slowly growing or latent and later accelerated growth, just like those of
patients who have metastasis diagnosed 10 to 20 years after enucleation.26;54;80;91;92;117
6.2.2. Tumor Doubling Times of Metastatic Uveal Melanoma During Treatment
The mean tumor doubling times averaged for the entire period of active treatment of the 18
patients who showed either stable disease (SD) or progressive disease (PD) ranged from 25 to
2619 days (median, 255). Five patients showed a partial response (PR) and thus would have
given negative doubling times. A scatterplot of calculated doubling times during treatment
against pretreatment doubling times did not suggest any correlation between them (Fig.6).
Current chemoimmunotherapy regimens for disseminated uveal melanoma have provided
few objective responses and no long term cures.4;5;17;21;44;58;70;75;97;106;110 Our findings,
however, reveal that the treatment likely had an effect on tumor doubling times. The median
doubling times during active treatment were generally considerably longer than at the
diagnosis of metastases. This may have been due in part to the fact that growth of metastases
may slow down when they become large, however.104;151 Given the rarity of objective
responses and the possibility of lead-time bias in median survival, tumor doubling times
might provide an additional criterion for comparing systemic treatment responses in
metastatic uveal melanoma.
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Fig.5. Inferred growth of primary and metastatic uveal melanoma, based on tumor doubling time of 154 days for
primary tumor and empiric clinical data for metastasis. The time of micrometastasis, point A, is estimated to be
2.9 years earlier than the diagnosis of the primary tumor, point B, and 5.1 years earlier than clinical diagnosis of
metastases, point C; points B and C are plotted at 800 mm3 and 17000 mm3, respectively, based on observed
median sizes of primary and metastatic tumors. At the time of micrometastasis, the primary tumor is estimated to
be 7 mm3 in size, and at the time of diagnosis of primary tumor, the metastases are estimated to be 0.5 mm3 in
size.
6.2.3. Limitations
Our study is the first one that uses clinical data to estimate doubling times of metastatic
uveal melanoma, but it is important to note its limitations. Firstly, the calculated doubling
times are based on estimates of the size of undetectable metastases.152 The resulting values
may be biased by the fact that some metastases probably were smaller than the sensitivity
limit of imaging in calculations at the time when the screening US was negative. If so, we
have underestimated their growth rate. This applies especially to the smallest third of
metastases, which possibly had simply disseminated later instead of growing more slowly. It
is therefore necessary to view the long doubling times in this study with great caution, even
though some of them may well be genuine. It is also possible that an occasional tumor may
have escaped detection at screening even if it was actually larger than the sensitivity limit
used in calculations. In that case, we have overestimated their growth rate, but this should be
less likely. To cover for both sources for bias, a sensitivity analysis using two additional
sensitivity limits was performed. Our curves converge towards a doubling time of 30 to 40
days, suggesting that this estimate can be used in planning of screening program.
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Fig.6. Scatterplot of mean tumor doubling
times calculated for up to three largest
metastases before and during treatment of
metastatic uveal melanoma. The diagonal
indicates equal doubling time before and during
treatment. No correlation was present between
these two variables. Five patients with partial
response and two patients with stable disease
and consequently extremely long doubling
times during treatment were excluded.
Secondly, the mathematical model used is based on constant exponential growth and the
estimates can only reflect average growth rates during the period between last negative
screening and diagnosis of metastases. The model used is not quite as accurate as the model
based on complex Gompertzian growth kinetics but is well accepted as first approximation.71
Serial imaging of metastases in patients who do not receive active therapy would be needed to
confirm our estimates. Our method of extrapolation to earlier stages of metastatic growth is
adventurous, because it is likely that growth rates were variable and potentially slower at the
time of micrometastasis.74;104;151 The finding that estimated doubling times did not correlate
directly with observed disease-free interval lends support to this idea. For these reasons, it is
possible that we have underestimated the time from micrometastasis to treatment of the
primary tumor.
Thirdly, for technical reasons, the analysis was based on a nonrandom subset of all patients
with metastatic melanoma during the study period. For example, patients who had not
participated in annual screening or had not attended a screening visit may have differed from
those who did.
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6.3. A PROGNOSTIC MODEL AND STAGING FOR METASTATIC UVEAL
MELANOMA (III)
As it is well established, the prognosis of metastatic uveal melanoma is poor with a median
overall survival from 2 to 9 months.16;58;70;110 In our study, many of the enrolled patients
participated in regular screening and were asymptomatic, since lead-time bias must be taken
into account. No tools have yet been available, however, to adjust for differences in case mix
between trials.
6.3.1. Patients
The mean age of the 91 patients (male:female, 47:44) at diagnosis of metastatic uveal
melanoma was 62 years (SD, 12; range, 23-86). The relapse-free interval ranged from 3
months to 9 years 8 months (median, 2 years 9 months; Fig.7A).
6.3.2. Symptoms and Participation in Annual Screening
Of 74 patients whose symptoms were recorded in detail, 31 (42%) were asymptomatic and
43 (58%) had symptoms from metastases. Of the 91 patients, 77 (85%) participated in annual
screening. Dissemination was diagnosed at a scheduled screening in 57 of these patients
(74%; 95% CI, 63-83), but 9 of them had recently developed symptoms. Signs or symptoms
led to diagnosis in 34 of the 91 patients (37%; 95% CI 27-48), including 20 of the 77 patients
(26%; 95% CI 17-37) who participated in annual screening.
6.3.3. Karnofsky Index
Karnofsky index was known for 82 patients, of whom 55 (67%) scored 100-90 (equivalent
to ECOG 0), 24 (29%) scored 80-60 (ECOG 1-2), and 3 (4%) scored 50 or less (ECOG 3–4).
6.3.4. Sites of Metastasis
Of the 91 patients, 73 (80%; 95% CI 71-88) had only hepatic metastases at diagnosis, 7
(8%) had only extrahepatic metastases, and 11 (12%) had both hepatic and extrahepatic
dissemination. Abdominal US was diagnostic in 75 of 84 patients (89%; 95% CI, 81-95) and
suggestive in 5 patients, all of whom were confirmed to have hepatic metastases.
A chest radiogram was negative in 70 of 79 patients (89%; 95% CI 79-95) and suggestive
of metastasis in 9 patients (11%; 95% CI, 5-21), all of whom had concurrent metastases in
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Fig.7. Cumulative frequency distribution plot for (A) disease-free interval, (B) the largest dimension of the
largest metastasis, and (C) serum lactate dehydrogenase, alkaline phosphatase and (D) transaminase levels at
diagnosis of metastases for 91 patients who had stage IVB uveal melanoma.
other organs diagnosed clinically or by abdominal US. Pulmonary metastases were confirmed
in 5 of the 9 patients.
6.3.5. Size of Metastases
The median largest dimension of the largest metastasis of 71 patients with measurable
lesions was 48 mm (range, 9-212; Fig.7B). This dimension tended to be smaller for patients
who participated in annual screening than for those who did not (median, 44 v 88 cm; P =
.057, Mann-Whitney U test).
The estimated median total, hepatic, and extrahepatic burdens of metastasis were 95 cm3
(range, 0.5-5434), 87 cm3 (range, 0.5-5434) and 32 cm3 (range, 0.5-375), respectively. The
estimated total (82 v 791 cm3; P = .045) and hepatic metastatic burden (78 v 791 cm3; P =
.012) were higher if the patient did not participate in annual screening.
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6.3.6. Liver Function Tests
The serum AP level was over the upper normal limit in 23 of 76 patients (30%; 95% CI 20-
42; Fig.7C), LD in 27 of 43 patients (63%; 95% CI 47-77; Fig.7C), AST in 21 of 58 patients
(36%; 95% CI 24-50; Fig.7D), and ALT in 24 of 66 patients (36%; 95% CI 25-49; Fig.7D).
6.3.7. Treatment
Of the 91 patients, 13 (14%) received chemotherapy and 53 (58%) received
chemoimmunotherapy, usually bleomycin, vincristine, lomustine and dacarbazine (BOLD)
with human leukocyte or recombinant alpha interferon97;107 that was given to 50 (76%) of the
66 patients who got systemic therapy. In addition, 9 patients underwent surgical resection and
11 patients palliative radiotherapy at some point.
6.3.8. Overall Survival
Although recent nonrandomized, prospective, single institution phase II trials report
median survival of even up to 24 months,43;75;113 the factors contributing to improved
prognosis have not been analyzed.
The patients in our series died of disseminated disease after a median interval of 8.4
months (95% CI 6.3-11.8; range 1 week to 73 months); 36 (40%; 95% CI 29-50) survived 1
year, 12 (13%; 95% CI 7-22) patients 2 years, and 4 (4%; 95% CI 1-11) patients 3 years (36,
38, 39 and 73 months). The survival was 12.0 months for those who received systemic
therapy. The one who survived 73 months was excluded from survival analysis as an outlier.
In our study, the design did not enable us to discriminate whether rapid progress was due
to ineffective therapy or aggressive disease. Not only are patients with smaller metastases
more probable candidates for chemotherapy, but they also may have less aggressive disease.
Consequently, they are more likely to stay on chemotherapy. If the disease is developing
rapidly despite therapy, it is most likely discontinued. Distinguishing between these two
possibilities is not mandatory, when time on chemotherapy is modeled as a confounding
factor. Whether long time on therapy is due to efficacy or less aggressive disease, it will
adjust for the confounding and help to quantitate contribution to prognosis of other factors of
interest. An alternative approach would be to stratify according to therapy, but that would
ignore variation in the length of treatment.
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Fig.8. Observed overall survival for 91 patients with stage IVB uveal melanoma according to (A) disease-free
interval, (B) participation in annual screening, (C) Karnofsky index, (D) the largest dimension of the largest
metastasis and (E, F) serum alkaline phosphatase level at diagnosis of metastases.
6.3.9. Overall Survival in Relation to Patient Characteristics
By Kaplan-Meier analysis, the gender (P = .46 log-rank test) and age of the patient (P=
.61) were not associated with overall survival.
If the relapse-free interval was shorter, overall survival was longer (Fig.8A; P = .044 log-
rank test for trend). Asymptomatic patients survived longer than those who had symptoms
from metastases (median, 12.1 v 5.7; P = .029). Patients who participated in annual screening
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tended to survive longer than those who did not (Fig.8B; median, 8.9 v 4.3; P = .081 log-rank
test), but survival from diagnosis of the primary tumor was comparable (P = .25).
Gragoudas and others agree that the asymptomatic patients have better overall survival
compared with symptomatic ones.58 Our study shows that the survival from the diagnosis of
the primary tumor does not differ between these categories and suggests that lead-time bias
could be responsible for these results. As regards lead-time bias, our analysis also showed that
patients who participated in the annual screening tended to survive longer after detection of
metastases. Patients who attended annual screening that included liver imaging were expected
to survive a median of 9 months, adjusting for time on chemotherapy, whereas patients who
were not screened survived a median of 4 months. None of our patients were screened only
with chest radiograms and LFTs, but such patients could be expected to survive somewhat
longer than those who are not screened.
Overall survival was strongly associated with Karnofsky index (Fig.8C; median, 13.2 v 2.7
v 1.2 months; P < .001 log-rank test for trend). Large dimension of the largest metastasis
(Fig.8D; P < .001) and, to a lesser extent, high total metastatic burden (P = .007) were
significantly associated with short survival.
High serum level of AP was significantly associated with short survival, whether evaluated
by the measured level or relative to the UNL (Fig.8E, F; P < .001). Median survival was 11.9
months if AP was within UNL, 2.5 months if it was less than 2.5 times the UNL, and 1.4
months if the level was higher than 2.5 times UNL.
The median overall survival was 12.0 months for those who received systemic therapy and
4.2 months for those who did not receive it.
6.3.10. Multivariate Analysis of Survival
In our study, the survival was analyzed with Cox regression. By univariate Cox regression,
Karnofsky index, the largest dimension of the largest metastasis, total metastatic burden,
serum AP, AST, ALT and LD levels, and time on chemotherapy were strongly associated
with survival (P < .001; Table 7). Presence of symptoms was also associated with survival (P
= .031). Adjusting for time on chemotherapy by bivariate regression strengthened the
association between survival, presence of symptoms (HR 2.57 v 1.69; P <.001) and regular
screening (HR 2.14 v 1.67; P = .012), but decreased the association with Karnofsky index,
size of largest metastasis, total metastatic burden, and LFTs (Table 7).
A multivariate model, based on 54 patients with complete data, which adjusted for time on
chemotherapy and evaluated presence of symptoms (which had a higher bivariate Wald chi-
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square value than participation in annual screening), Karnofsky index, the largest dimension
of the largest metastasis (higher bivariate Wald chi-square than total metastatic burden), and
serum AP level (highest bivariate Wald chi-square of all LFTs) as independent variables was
considered first (Table 8). Karnofsky index (P= .037) and the largest dimension of the largest
metastasis (P = .020) retained independent prognostic significance in the starting model
(Table 8).
The two least significant variables were dropped one at a time to reduce the number of
covariates to four. Of the two competing models, the one that included presence of symptoms
(P = .060) had stronger association with overall survival than the one which included AP level
(Table 8; –2 log likelihood, 247.75 v 274.82, P < .001 Chi-square test, 1 degree of freedom).
The latter model, however, lended itself better for categorization. In this model, the Karnofsky
index (HR 2.24 for each category change; P = .013), the largest dimension of the largest
metastasis (HR 1.22 for each 10 mm increase; P = .003) and the serum AP level (HR 1.25 for
each 100 IU/l change; P = .042) retained independent prognostic significance (Table 8).
We tried to consider different aspects relevant to the clinical situation in building of the
regression model. Karnofsky index as a measure of general health and the largest dimension
of the largest metastasis as a measure of gross disease entered the multivariate model. An
advantage is that measuring the largest diameter of one metastasis is very easy for the
clinician, compared to calculating tumor burden as the total volume of all measurable
metastases.
The choice of the third independent variable had to be based both on practical and
statistical considerations. Although dropping serum AP from the model gave a statistically
stronger association with overall survival than dropping presence of symptoms, both models
identified each included variable as a statistically significant, independent predictor of
prognosis. The latter model is probably more suitable for clinical and research practice.
Whether a patient has symptoms is a matter of interpretation. Consequently, the effect
quantitated from our retrospective data set may be biased, and two clinicians may not agree
even if they query symptoms prospectively. Instead, serum AP is measured accurately, and
this also applies to retrospective data collection. Also, because it is possible to build a
multivariate model which fits well in a small sample but is not generalizable, the evidence
does not justify assigning priority purely on statistical grounds.
As uveal melanoma is likely to metastasize into the liver, LFTs are routinely performed.
They may reflect the combined effect of deranged liver function and overall metastatic
burden, because serum LD is a prognostic marker also for metastatic cutaneous melanoma,134
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which less frequently metastasizes to the liver. Our finding that serum AP level is an
independent predictor of survival even when controlling for measurable metastases suggests
that LFTs also may reflect unmeasurable disease. This is a further reason why it is appealing
to allow AP in the model.
In our series AP is the LFT most often performed to detect metastatic uveal melanoma.
However, AST, ALT, LD, and GGT are likewise associated with survival by univariate
analysis.16;75 We chose AP, because it showed the strongest association with survival in our
dataset. An advantage is that the model can be retrospectively applied to the largest possible
number of patients with stage IVB uveal melanoma. However, because serum LD level was
known for less than half of our patients, which might have affected our statistics, and because
LD is a recognized prognostic factor in stage IV cutaneous melanoma, the validity of
choosing AP instead of LD must be confirmed by analyzing representative independent
datasets.
6.3.11. Working Formulation for Staging Metastatic Uveal Melanoma
Recently The American Joint Committee on Cancer revised the staging of cutaneous
melanoma.13 No categorization was proposed for stage IV. We feel that, as regards stage IVB
uveal melanoma (as of January 2003; Stage IV), an effort to categorize is warranted because a
prognostic model would be a useful aid to assess prognosis in clinical practice, to decide
which patients to enroll and how to stratify them, and to interpret clinical trials.
In this study patients who would normally be eligible for chemotherapy were categorized
into three groups based on predicted median overall survival. The coefficients of the final
model were entered into the general Cox equation, adjusting for time on chemotherapy using
the population mean (5 months). A table of predicted median survival was compiled for
clinically relevant combinations of Karnofsky index, serum AP level and the largest
dimension of the largest metastasis (Table 9). Based on the predicted survival, the table was
divided in three to categorize stage IVB uveal melanoma. The 53 patients who had complete
data and whose Karnofsky index was over 50 were staged in the three categories. Kaplan-
Meier analysis (Fig.9A) indicated that observed median survival for stage IVBa was 14.4
(95% CI 11.7-21.3), for stage IVBb 8.9 (95% CI 2.7-13.7), and for stage IVBc 2.0 (95% CI
1.0-3.7) months. Scatterplot of predicted median against observed overall survival indicated
that the model differentiated survival between stages IVBa and IVBc (Fig.9B).
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Table 7. Cox proportional hazards regression of overall survival after diagnosis of metastatic
uveal melanoma.
  Regression
  coefficient Wald Hazard ratio
Variable (standard error)    χ2    P   (95% CI)
UNIVARIATE ANALYSIS
Gender* –0.157 (0.214)   0.53   0.463   0.85   (0.56-1.29)
Age†   0.032 (0.005)   0.41   0.157   1.03   (0.93-1.14)
Largest basal diameter of
  primary tumor‡ –0.016 (0.027)   0.38   0.54   0.98   (0.97-1.04)
Mode of diagnosis§   0.748 (0.225) 11.10 <0.001   2.11   (1.36-3.28)
Karnofsky index¶   1.223 (0.215) 32.49 <0.001   3.40   (2.23-5.18)
Presence of symptoms**   0.526 (0.244)   4.67   0.031   1.69   (1.05-2.73)
Largest dimension of largest
  metastasis††   0.152 (0.030) 25.10 <0.001   1.16   (1.10-1.24)
Estimated total metastatic
  burden‡‡   0.427 (0.119) 12.88 <0.001   1.53   (1.21-1.93)
S-AST§§   0.247 (0.045) 30.03 <0.001   1.28   (1.17-1.40)
S-AST >2.5 UNL¶¶   2.468 (0.692) 14.29 <0.001 11.80   (3.28-42.4)
S-ALT§§   0.172 (0.047) 15.54 <0.001   1.19   (1.08-1.30)
S-ALT >2.5 UNL¶¶   1.328 (0.526)   6.92   0.009   3.98   (1.42-11.2)
S-AP***   0.397 (0.070) 32.04 <0.001   1.49   (1.30-1.71)
S-AP >2.5 UNL¶¶   2.037 (0.552) 13.61 <0.001   7.67   (2.60-22.6)
S-LD***   0.054 (0.013) 16.97 <0.001   1.06   (1.03-1.08)
S-LD >2.5 UNL***   2.130 (0.406) 27.46 <0.001   8.42   (3.80-18.7)
Time on chemotherapy††† –0.122 (0.022) 29.59 <0.001   0.88   (0.85-0.92)
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BIVARIATE ANALYSIS – Adjusted for time on chemotherapy
Mode of diagnosis§   1.072 (0.238) 20.34 <0.001   2.92   (1.83-4.65)
Karnofsky index¶   0.859 (0.227) 14.29 <0.001   2.36   (1.51-3.69)
Presence of symptoms**   0.944 (0.264) 12.82 <0.001   2.57   (1.53-4.31)
Largest dimension of largest
  metastasis††   0.156 (0.064) 25.81 <0.001   1.17   (1.10-1.24)
Estimated total metastatic
  burden‡‡   0.454 (0.117) 14.98 <0.001   1.57   (1.25-1.98)
S-AST§§   0.219 (0.046) 22.94 <0.001   1.25   (1.14-1.36)
S-AST >2.5 UNL¶¶   2.058 (0.654)   9.92   0.002   7.84   (2.18-28.2)
S-ALT§§   0.204 (0.042) 23.91 <0.001   1.23   (1.13-1.33)
S-ALT >2.5 UNL¶¶   1.222 (0.528)   5.38   0.021   3.39   (1.21-9.55)
S-AP***   0.356 (0.072) 24.60 <0.001   1.43   (1.24-1.64)
S-AP >2.5 UNL¶¶   1.607 (0.552)   8.47   0.004   5.00   (1.69-14.7)
S-LD***   0.049 (0.013) 13.99 <0.001   1.05   (1.02-1.08)
S-LD >2.5 UNL¶¶   1.861 (0.409) 20.70 <0.001   6.42   (2.88-14.3)
* Coding: Male = 0; Female = 1
† Continuous variable, per 5 years
‡ Continuous variable, per millimeter (mm)
§ Coding: Diagnosed at screening = 0; Diagnosed because of symptoms = 1
¶ Coding: 100-90 = 1; 80-60 = 2; 50-0 = 3
** Coding: Asymptomatic = 0; Symptomatic = 1
†† Continuous variable, per cm
‡‡ Continuous variable, per 1000 cm3
§§ Continuous variable, per 10 International Units (UI)
¶¶ Coding:  2.5 x the upper normal limit = 0;  2.5 x the upper normal limit = 1 (Upper normal limits: S-
AST and S-ALT: males = 50 UI, females = 35 UI; S-AP = 275 UI; S-LD = 450 UI)
*** Continuous variable, per 100 International Units (UI)
††† Continuous variable, per months
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Table 8. Cox proportional hazards regression of survival after diagnosis of metastatic uveal
melanoma. Time on chemotherapy included as a confounding factor.
  Regression
  coefficient Wald Hazard ratio
Variable (standard error)    χ2    P   (95% CI)
MULTIVARIATE ANALYSIS
Model 1 (Likelihood ratio, –136.3 )
Time on chemotherapy††† –0.130 (0.033) 15.05 <0.001   0.88   (0.82-0.94)
Mode of diagnosis§   0.582 (0.386)   2.28   0.132   1.78   (0.84-3.81)
Karnofsky index¶   0.795 (0.329)   5.86   0.016   2.21   (1.16-4.22)
Largest dimension of largest
  metastasis††   0.194 (0.066)   8.76   0.003   1.21   (1.07-1.38)
S-AP***   0.147 (0.120)   1.51   0.219   1.16   (0.92-1.47)
Model 2 (Likelihood ratio, –176.4)
Time on chemotherapy ††† –0.100 (0.027) 13.99 <0.001   0.90   (0.86-0.95)
Mode of diagnosis§   0.649 (0.345)   3.53   0.060   1.91   (0.97-3.76)
Karnofsky index¶   0.515 (0.284)   3.28   0.070   1.67   (0.96-2.92)
Largest dimension of largest
  metastasis††   0.152 (0.051)   9.00   0.003   1.16   (1.05-1.29)
Model 3 (Likelihood ratio, –137.4) – Final Model
Time on chemotherapy* –0.118 (0.031) 14.14   <0.001   0.89   (0.84-0.95)
Karnofsky index¶   0.807 (0.325)   6.15   0.013   2.24   (1.18-4.24)
Largest dimension of largest
  metastasis††   0.197 (0.066)   8.88   0.003   1.22   (1.07-1.39)
S-AP***   0.221 (0.109)   4.16   0.042   1.25   (1.01-1.54)
For categories and coding, see Table 7.
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Our working formulation can be tested as a guide in estimating overall survival in clinical
practice and in comparing risk between given sets of covariates. For example, a patient whose
Karnofsky index is 100, largest metastasis is 40 mm and AP level is 350 U/l would be
predicted to live twice as long as one whose Karnofsky index is 80, largest metastasis is 60
mm and AP level is 250 IU/l (median survival 12 v 6 months).
As this far no randomized trials have been launched due to the rarity of metastatic uveal
melanoma, we recommend reporting working formulation categories in the future to enable
more meaningful evaluation of results. For example, if all patients who were enrolled
participated in liver imaging and were asymptomatic they should represent stage IVBa, and a
median survival of 14 months would be expected and suggestive of limited treatment effect.
Had all enrolled patients been of stage IVBb, a median survival of 14 months would be
unexpected and suggestive of a survival gain of about 5 months. Finally, we reiterate that the
working formulation is provisional and subject to change until verified with independent
datasets, and we encourage studies to that effect.
Table 9. Categorization of Stage IV metastatic uveal melanoma into three subgroups according to the predicted
median survival, in months, based on Karnofsky index, serum alkaline phosphatase (S-AP) and largest
dimension of the largest metastasis*
Largest Dimension of Largest Metastasis
(mm)
 Karnofsky
   Index
 S-AP Level
     (U/l)
20 40 60 80 100
100-90 250  A   14 12 11 8 7
350 13 12 8 8 6
450 12 11 8 6 5
550  B    11 8 7 6 4
80-60 250 11 8 6 6 4
350 8 8 6 4 3
450 8 6  C    5 4 2
550 7 6 4 3 2
* Data express predicted median survival in months. Stage IVA corresponds to predicted survival of 12
months or more, Stage IVB to predicted survival of 6-11 months, and Stage IVC to predicted survival of less
than 6 months. Calculated from the final Cox proportional hazards regression model given in Table 8.
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Fig.9. Observed overall survival for 53 patients with stage IVB uveal melanoma by subcategory (stage IVBa,
IVBb, IVBc). (A) Patients were assigned to the subcategories based on predicted median survival calculated
from Karnofsky index, serum alkaline phosphatase level and largest dimension of the largest metastasis at
diagnosis. (B) Scatterplot of predicted median against observed overall survival by subcategory.
6.3.12. Limitations
A distinctive strength of this study is that the series is essentially population-based and
consecutive. As in study II the main limitations of this study are retrospective collection of
data and small sample size. However, most data consist of dates and laboratory results from
patient charts, which leave little scope for error. Measurements taken from images might have
been more precise in a prospective study and recording of symptoms would certainly have
been more accurate. Given the small sample, number of variables in the Cox multivariate
model was limited, but it was not feasible to set aside a validation sample. In spite of these
limitations, we believe that the results can be generalized to other Caucasian patients with
metastatic uveal melanoma.
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6.4. MODE OF PRESENTATION AND TIME TO TREATMENT OF UVEAL
MELANOMA IN FINLAND (IV)
This retrospective survey of referral to treatment of patients with primary uveal melanoma
identified several differences as compared with a previous prospective analysis conducted in
the United Kingdom.3;30;31;67
6.4.1. Symptoms
Out of 159 patients, 139 (87%; 95% CI 81-92) had symptoms prior to their first contact
with health care, most commonly blurred vision and a visual field defect (Table 10). The
symptoms appeared a median of 84 days previously (range, 0 days-5 years 11 months), and
119 patients (86%; 95% CI 79-91) sought help because of the symptoms. The other 20
patients (13%; 95% CI 8-19) made or kept an appointment made for other reasons, most
commonly to change spectacles and to attend a scheduled screening examination for a
presumed nevus (Table 11).
Intraocular tumor was diagnosed or suspected in 20 entirely asymptomatic patients (13%;
95% CI 8-19) during an appointment made for various reasons, again most often to change
spectacles and to attend a scheduled nevus screening examination (Table 11).
In our series, the tumor was diagnosed in one eighth (13%; 95% CI 8-19) of patients
during a routine visit without symptoms. The proportion of asymptomatic patients was one
third of that in the British studies, in which 30-45% of patients were asymptomatic.30;67 This
difference suggests that ophthalmic opticians in United Kingdom who perform
ophthalmoscopy, may be better accessible than ophthalmologists in Finland. The British
might also be better informed about the advantages of routine ocular check-ups, or presence
of symptoms may have been coded differently.
As regards the mean age of the patients (59.7 vs. 60.6 years), mean LBD of the tumor (11.6
vs. 11.3 mm), and mean duration of symptoms before first contact (2.2 vs. 3.1 months) the
British and Finnish series were comparable31;67 and do not suggest a systematic difference in
accessibility to treatment. The larger mean tumor thickness of Finnish patients (4.9 vs. 6.4
mm) remains unexplained because both values were based on basically identical
ultrasonographic measurements.
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6.4.2. Initial presentation
The first health care professional contacted was a dispensing optician in 24 cases (15%,
95% CI 10-22), a nonophthalmologist in 30 cases (19%, 95% CI 13-26) and an
ophthalmologist in 104 cases (65%, 95% CI 58-73). Prior to the first visit related to the tumor,
39 patients (25%, 95% CI 18-32) had seen a dispensing optician a median of 24 months
earlier (range, 3 weeks-15 years 11 months), and 104 patients (65%; 95% CI 58-73) had seen
an ophthalmologist for unrelated reasons a median of 26 months previously (range, 3 months–
19 years 11 months) (Fig.10).
Of Finnish patients, 45 (28%) had seen an ophthalmologist for reasons unrelated to the
tumor less than two years before the initial presentation. In some of such cases it may be that
an examination had not been carried out thoroughly. The British studies did not include
comparable information.
Table 10. Symptoms before diagnosis of primary uveal melanoma in 159 Finnish patients.
Symptom N %* 95% Confidence Interval
Blurred vision 78 49 41-57
Visual field defect 51 32 25-40
Photopsia 29 18 13-25
Irritation and pain 26 16 11-23
Metamorphopsia 10 6 3-11
Floaters 9 6 3-10
Redness 9 6 3-10
Pressure 8 5 2-10
Change in appearance 4 3 1-6
Other symptoms† 17 11 6-17
Asymptomatic 20 13 8-19
* Patients typically had more than one symptom
† Headache (5), change in color perception (3), tearing and discharge (3), diplopia (1), convergence
insufficiency (1), oscillating vision (1), photophobia (1), tic (1), subconjuctival hemorrhage (1).
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6.4.3. Diagnosis and referral
The diagnosis made during the first visit was mentioned in 111 of the 159 (70%) patient
charts. A tumor was mentioned in 77 (69%) of them.
The dispensing optician referred 21 of 24 patients (88%; CI 95% 68-97) to a private
ophthalmologist. Two patients were referred to a nonophthalmologist. The only patient who
was not referred had seen floaters for three months and received a prescription for spectacles.
Dispensing opticians do not make diagnoses.
The nonophthalmologist referred 26 of 30 patients (87%) to an ophthalmologist. An
intraocular tumor was mentioned in two referral letters. Of 25 patients who sought help
because of tumor symptoms, 4 (16%) were not referred but were treated for presumed tension
neck syndrome, conjunctivitis, blepharitis, and floaters interpreted to be a symptom of
concurrent high blood pressure. All four contacted an ophthalmologist within 3 months. Of
the 5 patients who made contact for unrelated reasons, 4 had ocular symptoms and 1 had
tumor diagnosed when fundi were examined for diabetic retinopathy. All five were referred.
Of 104 patients seen first by an ophthalmologist, 23 (22%) were though to have findings
typical of uveal melanoma, and 44 (42%) were diagnosed to have an unspecified intraocular
Table 11. The reason for making appointment for 40 patients with primary uveal melanoma
who did not seek help because of symptoms
    Recently    Entirely
__symptomatic*__ _asymptomatic_ ___Total_____
Reason for appointment N %  (95% CI) N % (95% CI) N % (95% CI)
Spectacle prescription 8 5% (2-10) 7 4% (2-9) 15 9% (5-15)
Nevus screening 4 3% (1-6) 5 3% (1-7)  9 6% (3-10
Health check-up 3 2% (0-5) 1 1% (0-3)  4 3% (1-6)
Unrelated surgery 1 1% (0-3) 2 1% (0-4)  3 2% (0-5)
Diabetic retinopathy 1 1% (0-3) 1 1% (0-3)  2 1% (0-4)
Glaucoma 0 0% (0-2) 2 1% (0-4)  2 1% (0-4)
Other cause† 3 2% (0-5) 2 1% (0-4)  5 3% (1-7)
* The symptoms developed after the appointment was made
† Screening because of cataract (2), systemic medication (2), and congenital toxoplasmosis (1)
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tumor. A suspicious nevus was diagnosed in 7 patients (7%) of whom 3 were referred and the
rest scheduled for follow-up. Thus, 74 patients (71%; 95% CI 61-80) were diagnosed to have
a tumor during the first appointment. However, only retinal detachment was diagnosed in 7
patients (7%) and five patients were referred because of acute glaucoma, uveitis, cataract,
vitreous hemorrhage, and an unidentified fundus lesion, one case of each. In 3 of them the
tumor was not visible before the secondary problem had been treated. In 10 instances (10%),
the reason for referral was not specified.
Of the other 7 patients (7%) who were not referred, 4 were diagnosed to have a refractive
error and received spectacles, and the reason for floaters and visual field defect was not
identified in 3 patients. All made a new appointment (one saw a dispensing optician who
referred him back to the ophthalmologist). During the second visit, 4 of them were diagnosed
to have a tumor, one a retinal detachment, and one an unidentified fundus lesion. One tumor
still remained undiagnosed and the patient was referred with headache and blurring of vision
to a family physician, who suspected a tumor a year later.
Based on our data on uveal melanoma patients in Finland, two out of three seek help from an
ophthalmologist whether they have symptoms or not. The probability for them to be
immediately referred and correctly diagnosed at first visit was 88% and 71%, respectively.
One fifth consulted family practitioners and other nonophthalmologists, and one sixth saw a
dispensing optician. They had 88% and 87% chance of being immediately referred,
respectively, and 13% of those referred by a nonophthalmologist were diagnosed correctly.
Fig.10. Cumulative frequency plot of the time
span between the last visit unrelated to the
tumor to an ophthalmologist and to a
dispensing optician and initial presentation
with the tumor.
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In Finland, the dispensing opticians do not give diagnoses. In Britain, 59% of patients saw
first an ophthalmic optician, and only 14% an ophthalmologist.67 We had an impression that
the choice of a health care professional was dictated by availability and personal preference
rather than concern related to symptoms (Table 1). Uveal melanomas are relatively rare and it
is likely that the patients did not know that the symptoms might be serious.
It is disappointing, but also a sign of sometimes so difficult diagnosis making, that an
intraocular tumor apparently was missed by an ophthalmologist in 29% (95% CI 20-39) of
patients during the first visit. What is even more important is that most of them were
nevertheless referred because of secondary effects of the tumor. Moreover, some of our
patients had seen an ophthalmologist for unrelated reasons during previous month(s) without
the tumor being diagnosed. The proportion was comparable in the British study, in which
misdiagnosis occurred in 4 of 16 patients (25%; 95% CI 7-52) seen by an ophthalmologist.67
Misdiagnosis rate was 15% when patients presented first to an ophthalmic optician in U.K.30
This implies a need for further education as regards signs and symptoms of intraocular tumors
and emphasizes the importance of dilated fundus examination by indirect ophthalmoscopy,
which may not have been carried out in every instance.
6.4.4. Melanomas developing from nevi
The question of following up choroidal nevi is a constant topic of debate. Various views of
screening have been presented and several high-risk characteristics have been identified as a
useful aid to predict growth of small choroidal melanocytic tumors; such as presence of
symptoms and subretinal fluid, tumor thickness greater than 2 mm, orange lipofuscin pigment
over the tumor, and tumor margin touching the optic disc.123;127 The Collaborative Ocular
Melanoma Study Group reported three additional features associated with growth: larger basal
diameter, absence of drusen, and absence of retinal pigment epithelial change adjacent to the
tumor.144 Of 11 choroidal nevi, 10 (91%) had at least 1 risk factor for growth. Seven nevi
(36%) were associated with 3-4 of the 8 known high-risk characteristics for growth.
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In Finland, of the 159 patients, 13 (8%) developed a melanoma from a previously
identified presumed nevus. In 9 of them the melanomas were diagnosed in a scheduled
screening (69%; Table 12), the others were not followed up systematically. The median
follow-up time before diagnosis of uveal melanoma was 3 years (range, 1–35 years) and the
screening interval 12 months (range, 3 months - 2 years). Despite screening, in 8 of the 13
(62%) eyes, symptoms developed before diagnosis.
The median LBD of the presumed nevus at first examination was 6.0 mm, height 1.0 mm,
and volume 19 mm3. When uveal melanoma was diagnosed, the median LBD had increased
by 1.7 times to 10 mm, the height by 3.5 times to 3.5 mm, and the volume by 7.5 times to 142
mm3.
Roughly one out of ten uveal melanomas in this population-based study developed from a
known presumed nevus. The proportion who had a previous nevus was roughly the same, 3 of
50 patients in the British study.3 This is likely to be an underestimate, because a third of our
patients had not seen an ophthalmologist before and because nevi in the peripheral fundus
may escape attention. It is of note that 10 of the 11 presumed nevi that developed a melanoma
were initially associated with at least one of the eight known high-risk characteristics for
growth. In particular, 8 had developed symptoms since last screening. We suggest that follow-
up of presumed nevi would be ideally based on fundus photographs and, when the nevus is
elevated, on ultrasonographic measurements. The smaller the nevus is, the more difficult it is
to observe growth only by ophthalmoscopy, and this applies particularly to change in tumor
height. Thus, the tumors in our study were on average almost twice as large by LBD at
diagnosis of uveal melanoma than initially, but their median volume was seven times bigger.
Prior growth was thus probably missed or overlooked which emphasizes the importance of
referring small suspicious tumors for second opinion at an early stage and of following them
with photography and ultrasonography, especially as tumor doubling times suggest that
micrometastasis may take place one to five years before diagnosis of primary tumor in two
thirds of patients with metastases. Patients with nevi should also be told to return immediately
if any visual symptoms develop.
6.4.5. Number of visits and delay times
The median number of visits before treatment was 4 (range, 2-23) including a visit to a
regional hospital to rule out other malignancies and metastases and treatment planning visit to
the ocular oncology service.
Results and Discussion
71
The median time from initial presentation to treatment planning was 35 days (range, 0-
1426). When the first contact was a dispensing optician the median was 22 days (range, 1-
1156), when a nonophthalmologist was contacted it was 68 days (range, 0-1283), and when
an ophthalmologist was consulted, the median delay was 34 days (range, 1-1426). The
differences in delays were not statistically significant (P = 0.16, Kruskal-Wallis test).
Whether the tumor was suspected during the first visit or not did not statistically
significantly affect the delay before treatment planning (Fig.11A; 77 patients vs. 82 patients,
median, 34 days vs. 49 days, P = 0.15 Mann-Whitney U-test).
In our dataset, 25 patients (16%; 95% CI 10-22) were recognized to have been
misdiagnosed or to have had administrative problems related to their referral. The delay
before treatment planning for these 25 patients was statistically significantly longer than that
of patients who had not experienced such a problem (Fig.11B; median, 101 days vs. 34 days,
P = 0.001).
The British study identified avoidable delay in referral in 42% (95% CI 28-57) of 50
patients.3 Based on the same categorization, 16% (95% CI 10-22) of our patients encountered
a similar delay in referral. In Finland the specialist at the receiving unit decides the urgency of
the referred patient based on the information in the letter. The British study speculated that
reassurance that symptoms are not serious leads to late diagnosis,3 but the Finnish patients
usually searched rapidly a new consultation when symptoms persisted.
One cause of delay in our study was the waiting time to imaging of the liver in regional
hospitals which are financial gatekeepers as regards referral to the ocular oncology service.
Waiting for special investigations also caused delay in Britain, where the most important
delay was referral to an ophthalmologist via a general practitioner,31;67 also a financial
gatekeeper. We did not find difference in delays whether or not the patient was seen first by
an ophthalmologist or other health care professional, and whether or not a tumor was
immediately suspected.
Even if the delay might not affect survival, patients feel most distressed during the interval
from suspicion of a tumor to eventual treatment after which the stress diminishes.29
Because micrometastasis may take place between 1 and 5 years before diagnosis,84;86 a
median delay of less than 4 months from the onset of symptoms to treatment may not always
represent a serious hazard to life, but a shorter delay could potentially salvage more useful
vision and perhaps prevent some metastases from developing. These findings also seem to
indicate that an earlier diagnosis in several instances might be possible if routine dilated
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fundus examinations were performed without exception. Routine referral of patients with
suspicious nevi for second opinion could also reduce delay in a subgroup of patients.
6.4.6. Tumor dimensions and treatment
The median time from initial presentation to the treatment was 57 days (mean, 126 days;
range, 6-1435). Of the 159 patients, 8 (5%) were treated within 2 weeks from the initial
presentation and the delay was longer than 20 weeks in 33 (21%) instances.
None of the patients had clinical metastases at diagnosis. The median height of the
melanoma was 6.0 mm (mean, 6.4 mm; range, 1.0-17.0), LBD was 11.0 mm (mean, 11.3 mm;
range, 2.5-22.0), and volume 286 mm3 (mean, 484 mm3; range, 5-3686). The presence of
tumor symptoms (P = 0.16; Mann-Whitney U-test) and tumor volume (r = - 0.89; P = 0.29;
Spearman’s rank correlation) were not statistically associated with the delay but a tendency of
large and medium-sized melanomas being diagnosed earlier than small ones was present
when compared according to categorized tumor sizes (Fig.11C, P= 0.068; Kruskal-Wallis
test).
The median time from treatment planning to treatment was 11 days (mean 16 days; range,
0-126). Of the 159 patients, 100 (63%) were treated within 2 weeks and 126 (79%) within 3
weeks time. Delays less than 3 weeks were related to waiting for the appropriate plaque to be
ready from previous treatment. Delays longer than 3 weeks occurred when an indeterminate
tumor was first observed for growth, vitreous hemorrhage initially made the diagnosis
uncertain, further investigations to rule out metastasis were needed, and when required by the
patient because of intercurrent disease, personal reasons, or need for second opinion.
Brachytherapy with ruthenium and iodine plaques was given to 81 (51%) and 63 (40%)
patients, respectively. The involved eye was enucleated from 11 (7%) patients and 4 tumors
were treated with local resection. A statistically significant association was found between the
delay and type of brachytherapy. The median delay was 59 days (range, 4 days-3 years 6
months) for patients who underwent ruthenium plaque therapy and 33 days (range, 0 days-2
years 10 months) for those who underwent iodine brachytherapy (Fig.11D; P = 0.009; Mann-
Whitney U-test).
In Britain, patients who were promptly referred were more likely to be treated with eye-
and vision-conserving methods.3 In Finland, no such difference emerged partly because of
much more common use of iodine plaque radiotherapy instead of enucleation for large
tumors. However, an unforeseen difference was noticed between the two modes of
brachytherapy. Ruthenium brachytherapy, used for smaller melanomas, was paradoxically
Results and Discussion
73
Fig. 11. Cumulative frequency plots of time from the initial presentation to treatment planning in the national
ocular oncology service according to (A) the health care professional seen. One patient referred by a school
nurse is omitted, (B) whether or not misdiagnoses or administrative problems occurred in the referral process.
(C) categorized tumor size (Kruskal-Wallis test), and (D) the type of brachytherapy (Mann-Whitney U-test).
associated with longer delays than iodine brachytherapy, given to patients who have larger
tumors. Even though we did not find statistically significant differences in delay according to
tumor size this finding suggests that larger melanomas caused more symptoms and were
easier to diagnose and were thus also treated faster.
6.4.7. Limitations
Because of its retrospective nature, this study was liable to missing and erroneously
recalled data. Checking the data against patient charts and other legal documents have
minimized this problem. The number of patients was small, but this is compensated for by the
fact that the present series was population-based, consecutive, and had a high inclusion rate.
We believe that the results reflect the current referral for uveal melanoma in Finland
reasonably well.
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6.5. FUTURE DIRECTIONS
This study was planned and carried out to help physicians to detect primary and metastatic
uveal melanoma as early as possible and to understand the clinical course of disseminated
disease. By earlier diagnosis, better survival and quality of life might be achieved, although
the diagnostic delay, when present, was generally found to be relatively short with regard to
the predicted time of micrometastasis. One may predict that efforts to combat micrometastasis
are likely to prove more successful in improving prognosis than pursuing an earlier diagnosis
of the primary tumor, which nevertheless remains a desirable goal.
Regarding management of disseminated uveal melanoma, the new information presented
in this thesis will help clinicians to:
1. Plan and organize screening programs for metastatic disease based on sensitivities and
specificities of various examinations available at the moment and schedule them
accordingly based on tumor doubling times. In the future one would like to have more
sensitive means of imaging hepatic and extrahepatic metastases, so that patients who
have metastases in either or both of these compartments can receive appropriately
targeted therapy. Neither computed tomography, magnetic resonance imaging nor
ultrasonography are perfect for this purpose.
2. Stratify patients who are enrolled into treatment trials for metastatic disease according
to predicted survival so as to obtain more valid data on the effect of therapy even when
randomization is not possible. The HUCH working formulation will also be an
important tool in evaluating survival results of different trials, but it still needs to be
validated by external data and it may need adjustments in the future if significant
development in diagnostic strategies and prognostication takes place. The advent of
adjuvant treatments may also require changes in the formulation.
3. Recognize procedures in their clinical practice that are inefficient and not evidence-
based as regards detecting, identifying and referring patients with intraocular
melanoma and suspicious nevi.
Future research must identify factors which influence the time that micrometastases need
to grow into clinical metastasis. If this time can be controlled and prolonged, it may be
possible to improve the prognosis of patients with uveal melanoma even if the metastases
cannot be totally cured.
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